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ABSTRACT

Background: The etiology of congenital heart valve defects is not well understood; little
is known about the risk factors that contribute to the survival and mortality outcomes of
children with these defects.
Methods: Using data from the Texas Birth Defects Registry (TBDR) we conducted a
retrospective cohort study of 2070 singleton infants with congenital aortic, pulmonary, or
tricuspid valve atresia or stenosis born in Texas between January 1, 1996 and December
31, 2007 to Hispanic, Non-Hispanic (NH) black, and NH white women. TBDR data were
death-to-birth matched by the Texas Vital Statistics Unit for deaths between January 1,
1996 and December 31, 2008. Using Kaplan-Meier survival estimates with log rank tests
and Cox proportional hazards regression model hazard ratios (HR) with 95% confidence
intervals (CI), we examined whether infant sex and maternal race/ethnicity affected early
childhood survival or risk of mortality for children with congenital heart valve defects.
Covariates included birth weight and gestational age, maternal age, maternal education,
and number of co-occurring birth defects.
Results: In children with aortic valve atresia and aortic valve stenosis, we found males
had higher early childhood survival than females (55.0% vs. 41.5%, P=0.0451 and 91.6%
vs. 82.5%, P=0.0492, respectively). Early childhood survival for males (94.9%) with
pulmonary valve stenosis was slightly lower than females (97.1%, P=0.0116), and was
viii

also lower for NH black (94.1%) and Hispanic (95.3%) children than NH white children
(97.8%, P=0.0340). After adjusting for covariates, early childhood mortality in children
with pulmonary valve atresia with hypoplastic right ventricle was greater in NH black
than NH white children (HR=2.93, CI 1.09-7.85, P=0.0329) and greater in NH black
males than NH white males (HR=4.63, CI 1.12-19.19, P=0.0349). For children with
tricuspid valve atresia, early childhood survival was lower in NH black males (35.7%)
and Hispanic males (64.0%) than NH white males (81.0%, P=0.0269); after adjusting for
covariates, risk for early childhood mortality was higher in NH black than NH white
children (HR=3.39, CI 1.41-8.13, P=0.0062), and higher in NH black males than NH
white males (HR=5.23, CI 133-20.58, P=0.0179).
Conclusions: Our findings demonstrate there are disparities in early childhood survival
and risk of mortality by infant sex and maternal race/ethnicity for children with
congenital heart valve defects. These findings provide a foundation for further
investigation to better understand why these disparities exist and what can be done to
improve the outcomes for children with these defects.
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CHAPTER 1:
INTRODUCTION AND BACKGROUND

Birth defects are a primary cause of infant mortality in developed nations
including the United States. Some of the most prevalent and fatal birth defects are
congenital heart defects (Cleves, Ghaffar et al. 2003). The prevalence of congenital heart
defects worldwide is approximately 8 per 1,000 live births (Samanek, Slavik et al. 1989;
Marelli, Mackie et al. 2007; Amorim, Pires et al. 2008; Reller, Strickland et al. 2008;
Bernier, Stefanescu et al. 2010; Wu, Chen et al. 2010). In the United States,
hospitalization costs associated with birth defects were greater than $2 billion in 2004,
and congenital heart defects represented more than 50% of these costs (Russo 2007).
Birth defect surveillance programs have been developed in many states, and data
from these registries are useful for public health research in identifying causes for the
development of prevention programs. Research has found differences in morbidity and
mortality between males and females with congenital heart defects (Boneva, Botto et al.
2001; Lary and Paulozzi 2001; Seifert, Howard et al. 2007; Nembhard, Pathak et al.
2008; Engelfriet and Mulder 2009; Gilboa, Salemi et al. 2010). Studies have also shown
racial disparity in prevalence, underlying cause of death, and survival for infants with
congenital heart defects (Sadiq, Stumper et al. 1995; Boneva, Botto et al. 2001; Botto,
Correa et al. 2001; Lary and Paulozzi 2001; Seifert, Howard et al. 2007; Nembhard,
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Pathak et al. 2008; Almond, Thiagarajan et al. 2009; Fixler, Nembhard et al. 2010;
Nembhard, Salemi et al. 2010; Nembhard, Wang et al. 2010; Nembhard 2011).
Congenital heart defect research has identified disparities, some of which are
within a subset of congenital heart defects: congenital heart valve defects. However, little
is known about mortality among infants with atresia and stenosis of the aortic,
pulmonary, and tricuspid valves.
Understanding the race/ethnicity and sex differences in survival and mortality for
infants with congenital heart valve defects can provide public health researchers and
clinicians with information necessary to guide population health strategies and health
care planning toward improving the lives of children and adults with these defects.
Evaluations of potential disparity in survival probability and the risk of mortality in
infants born with congenital heart valve defects are necessary to expand the current
understanding of the role of race/ethnicity and sex in the complex etiology of these
defects. Such knowledge will be useful in the development of prevention and treatment
protocols for congenital heart valve defects. Our study evaluates race/ethnicity and sex as
risk factors for congenital heart valve defect survival probability and risk of mortality.
ETIOLOGY OF CONGENITAL HEART DEFECTS
The etiology of congenital heart defects is unclear. There are numerous distinct
congenital heart defects with various degrees of severity that contribute to the difficulty
in clearly identifying the pathogenesis and etiology of the defects. Approximately 64% of
congenital heart defects are isolated defects, most of the remaining cases are included
with defects such as trisomies and syndromes (Botto, Lin et al. 2007). The cause for
congenital heart defects can be categorized as follows: chromosomal abnormalities,
2

single gene defects, environmental factors, and family history (Thompson, McInnes et al.
1991). Other risk factors for congenital heart defects that have been identified include any
of the following during pregnancy: maternal diabetes, maternal alcohol consumption,
maternal exposure to prescription or non-prescription drugs or chemicals, and mothers
who had rubella, rheumatic fever, or viral infection such as influenza during pregnancy
(Sadler 2000). As such, the etiology of congenital heart defects is best understood as a
complex interaction of environmental and genetic causes.
EMBRYOGENESIS OF THE HEART
Most congenital heart defects originate during the formation of the structure of the
heart – during the first six weeks of gestation. By the 15th day post conception,
mesoderm and ectoderm cells exist that will develop into the heart. Endocardial tubes are
formed from these cells by the 19th day, and these tubes fuse and form heart cells
(myocytes) by the 21st day. The heart starts beating on day 22 and blood is circulating by
day 24. During the 23rd to 28th days the heart tube folds and twists to form atria and
ventricles. Within the next two weeks the chambers of the heart form (Sadler 2000).
FETAL AND NEONATAL HEART DEVELOPMENT
Before birth, oxygen in the fetus’ blood is provided by the mother. There is an
opening between the right and left atrium, called the foramen ovale, through which blood
flows from the right to left atrium. Blood bypasses the fetus’ lungs through a blood vessel
that connects the aorta and pulmonary arteries (ductus arteriosus). After birth the lungs
fill with air, thereby reducing pulmonary resistance and increasing the blood flow from
the right atrium to the right ventricle and into the pulmonary arteries. This reduces the
flow of blood through the foramen ovale from the right atrium to the left atrium. These
3

changes result in the closing of the foramen ovale, and separation of the circulatory
system into left and right halves. Once the baby is breathing on its own, the ductus
arteriosus is no longer necessary and normally closes within days after birth (Moller and
Neal 1990).
CONGENITAL HEART DEFECTS
Congenital heart defects are structural heart abnormalities of the arteries and veins
near the heart, or the valves or walls within the heart, and are present at birth. Congenital
heart defects disrupt the normal flow of blood through the heart, causing blood flow to
slow down, flow in the wrong direction or to the wrong place, or be blocked completely
(Moss and Allen 2008). There are many types of congenital heart defects with varied
degrees of severity.
CONGENITAL HEART VALVE DEFECTS
In a normally functioning heart the flow of blood from the body through the heart
and back out to the body is properly regulated by the opening and closing of heart valves
with each heartbeat, as shown in Figure 1. Defective heart valves do not fully open or
allow blood to leak back into heart chambers. Congenital heart valve defects include, but
are not limited to: aortic valve atresia, aortic valve stenosis, pulmonary valve atresia,
pulmonary valve stenosis, tricuspid valve atresia, and tricuspid valve stenosis. Congenital
heart valve atresia is a defect that results when the valve fails to develop; stenosis is a
defect resulting from narrowing or constriction of the valve, wherein the flaps of the
valve do not fully open to allow enough blood to flow through (Moss and Allen 2008).
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Figure 1. Cross section of a healthy heart. (U. S. Department of Health and Human
Services).

NEED FOR THE STUDY
For nearly 20 years, researchers have reported disparities in risk factors for
congenital heart defects and also among congenital heart valve defects. However, not all
of the results of previous investigations agree. Limitations of previous studies include
limited accuracy of congenital heart defect diagnosis documentation (Strickland, RiehleColarusso et al. 2008; Mangones, Manhas et al. 2009; Nembhard and Loscalzo 2009),
and limitations of passive surveillance systems (Nembhard and Loscalzo 2009). In
addition, previous studies did not evaluate all congenital heart valve defects individually;
data for some defects were combined because of coding methods.
Perhaps the inconsistencies in results of previous investigations are due to
reporting or diagnosis errors; a study using data with confirmed diagnoses might
demonstrate stronger associations than have been observed in other studies. Verified data
5

are now available that clarify diagnoses for atresia and stenosis defect categories that
have historically been combined. These data could also improve misdiagnosis limitations
of previous studies.
Due to the variation in severity of heart valve defects, children with defects such
as pulmonary or aortic valve stenosis might be expected to have better survival than
children with pulmonary valve atresia (Samanek 1992; Samanek and Voriskova 1999).
However, an evaluation of survival and mortality by sex or race/ethnicity for children
with each specific congenital heart valve defect has not been reported. There is limited
published information on survival probability and risk of mortality by sex or
race/ethnicity for congenital heart valve defects. Our study determines survival and risk
of mortality among children with congenital heart valve defects by infant sex and
maternal race/ethnicity.
SPECIFIC AIMS AND HYPOTHESES
The purpose of this study was to evaluate risk factors associated with congenital
heart valve defects in children. This study assesses whether the probability of survival or
risk of mortality varies by infant sex or maternal race/ethnicity for each of six congenital
heart valve defects. Two study aims with specific sub-aims and hypotheses are
investigated. The study aims (1 and 2) intend to evaluate early childhood survival
probability and risk of mortality for infants or children with congenital heart valve
defects. Study sub-aims (a and b) further elucidate the evaluation of survival probability
and risk of mortality to determine if differences exist within the study population based
on infant sex or maternal race/ethnicity. The specific aims and hypotheses of this study
are:
6

Aim 1
To determine if early childhood survival probabilities vary by infant sex or
maternal race/ethnicity in children with congenital heart valve defects.
Sub-aim 1a
To determine if early childhood survival probability varies by infant sex for each
of the congenital heart valve defects.
H0: There is no difference in early childhood survival between males and females
for each type of congenital heart valve defect.
Sub-aim 1b
To determine if early childhood survival probabilities vary by maternal
race/ethnicity stratified by infant sex for each of the congenital heart valve defects.
H0: There is no difference in early childhood survival between Hispanic or NonHispanic (NH) black infants compared to NH white infants for each type of congenital
heart valve defect.
Aim 2
To determine if the risk of childhood mortality varies by infant sex or maternal
race/ethnicity stratified by infant sex in children with congenital heart valve defects, after
adjusting for potential confounders.
Sub-aim 2a
To determine if the risk of childhood mortality varies by infant sex for each of the
congenital heart valve defects.
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H0: There is no difference in risk of childhood mortality between males and
females for each type of congenital heart valve defect.
Sub-aim 2b
To determine if the risk of childhood mortality varies by maternal race/ethnicity,
after stratifying by infant sex, for each of the congenital heart valve defects.
H0: There is no difference in risk of childhood mortality between Hispanics or NH
blacks compared to NH whites for each type of congenital heart valve defect.
FINDINGS OF THE STUDY
The results of this study are presented in three manuscripts: the first manuscript
presents findings for maternal race/ethnicity and infant sex risk factors for early
childhood survival probability and risk of mortality in infants born with aortic valve
atresia and aortic valve stenosis. The second manuscript evaluates the hypotheses for
pulmonary valve atresia and stenosis, and the third manuscript presents findings for
tricuspid valve atresia. This research is significant because it advances knowledge from
previous investigations to better understand the effects of race/ethnicity and sex on early
childhood survival and mortality among infants born with these defects.

8

CHAPTER 2:
DISPARITIES IN SURVIVAL AND MORTALITY AMONG INFANTS WITH
CONGENITAL AORTIC VALVE DEFECTS BY MATERNAL
RACE/ETHNICITY AND INFANT SEX

ABSTRACT
Background: Little is known about racial/ethnic or infant sex differences contributing to
the survival and mortality outcomes of children with aortic valve atresia or aortic valve
stenosis.
Methods:

Using data from the Texas Birth Defects Registry, we conducted a

retrospective cohort study of 519 singleton infants born to Hispanic, Non-Hispanic (NH)
white, and NH black women in Texas between January 1, 1996 and December 31, 2007
with congenital aortic valve atresia and stenosis. We used Kaplan-Meier survival
estimates with log-rank tests and Cox proportional hazards regression ratios (HR) and
95% confidence intervals (CI) to determine, after adjusting for confounders, whether
infant sex or maternal race/ethnicity affects early childhood survival or risk of mortality
for these children.
Results: For children with aortic valve atresia and aortic valve stenosis, males had
higher early childhood survival than females (55.0% vs. 41.5%, P=0.0451 and 91.6% vs.
82.5%, P=0.0492, respectively). After adjusting for covariates, there was no statistically
significant differences in early childhood mortality between males and females with
9

aortic valve atresia (HR=0.89; CI 0.59-1.35; P=0.5840) or aortic valve stenosis
(HR=0.80; CI 0.37-1.73; P=0.5748). There were no racial/ethnic differences in risk of
early childhood mortality for children with either aortic valve atresia or aortic valve
stenosis.
Conclusion: Our study found that early childhood survival in males with aortic valve
atresia was better than survival in females with aortic valve atresia. Similarly, early
childhood survival in males with aortic valve stenosis was better than survival in females
with aortic valve stenosis. Our study did not identify race/ethnicity risk factors in the
survival or risk of mortality for children with aortic valve defects.
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INTRODUCTION
Birth defects are a primary cause of infant mortality and contribute more than half
of the reported hospitalization costs associated with birth defects in the United States
(Russo 2007). In order to improve the health and survival of infants and children, public
health researchers need to better understand risk factors associated with congenital heart
defects so that effective prevention and treatment programs can be developed and
implemented (Botto, Correa et al. 2001; Nembhard, Waller et al. 2001; Cleves, Ghaffar et
al. 2003; Nembhard, Salemi et al. 2007; Nembhard, Pathak et al. 2008; Nembhard,
Salemi et al. 2009; Fixler, Nembhard et al. 2010; Nembhard, Salemi et al. 2010). We
present our investigation of risk factors contributing to aortic valve atresia and aortic
valve stenosis, toward that goal.
Aortic Valve Stenosis
Aortic valve stenosis is the narrowing of the valve located between the left
ventricle and the aorta, resulting in restriction of oxygen-rich blood out of the heart to the
body. Aortic valve stenosis is an obstruction defect and is included in the category of
noncomplex left ventricular outflow tract obstruction malformations (i.e., aortic valve
stenosis, coarctation of the aorta, and hypoplastic left heart syndrome). It can occur with
patent ductus arteriosus, coarctation of the aorta, non-inlet ventricular septal defect, and
atrial septal defect, and severity varies considerably. Mild cases can be undetected in
early life; severe cases can cause heart failure in infants.
Table 1 provides a summary of literature findings for aortic valve defects. As
shown in the table, some studies did not differentiate aortic valve stenosis from aortic
valve atresia. The prevalence of aortic valve stenosis per 10,000 live births, ranges from
11

0.61 (95% CI 0.29-1.12) to 1.39 (95% CI 1.17-1.65) (Ferencz, Rubin et al. 1985; Pradat,
Francannet et al. 2003). Racial/ethnic disparity in the prevalence of aortic valve stenosis
has been reported. Correa-Villasenor (1991) reported an excess of aortic valve stenosis in
whites compared to blacks (OR=3.6; 95% CI 1.7-7.6). Fixler, Pastor et al. (1993) found
decreased risk of aortic valve stenosis in blacks than whites (blacks=0.07/1,000 live
births; whites=0.4/1,000; p<0.005), as did Botto, Correa et al. (2001) (RR=0.38; 95% CI
0.22-0.64). Carmichael, Shaw et al. (2004) found lower risk of aortic valve stenosis in
foreign-born Hispanics than NH whites (RR=0.7; 95% CI 0.6-0.8). Fixler, Pastor et al.
(1993) also found decreased risk of aortic valve stenosis in Mexican-Americans than
whites (0.20/1,000 vs. 0.4/1,000, respectively; p<0.05).
Aortic valve stenosis has consistently been found higher in males than females:
male to female ratio=2.41 (95% CI 1.84-3.25) (Pradat, Francannet et al. 2003); RR=2.52
(95% CI 1.61-3.75) (Forrester and Merz 2004); PR=2.71 (95% CI 1.70-4.31) (McBride,
Marengo et al. 2005); RR=1.51 (95% CI 1.11-2.07) (Lary and Paulozzi 2001); and boy to
girl ratio=1.95:1 (Samanek 1994).
Other studies have reported disparities in aortic valve defects, but did not study
aortic valve atresia and stenosis separately. Lubinsky (1997) reported more aortic valve
anomalies in males (76%) than females (24%). One study of data for 9,352 singleton
infants in Florida’s passive surveillance birth defects registry found that aortic valve
atresia/stenosis prevalence disparity was only statistically significant for male infants,
(RR=0.34, 95% CI 0.13-0.94) for black males compared to white males; and (RR=0.32,
95% CI 0.12-0.89) for Hispanic males compared to white males (Nembhard, Wang et al.
2010). Another study using these data found NH black and Hispanic infants had lower
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prevalence rates of aortic valve atresia/stenosis than NH white infants: (RR=0.46; 95%
CI 0.24-0.89) for NH blacks, and (RR=0.53; 95% CI 0.28-0.97) for Hispanics
(Nembhard, Salemi et al. 2010).
Survival during the first year of life of infants born with aortic valve stenosis is
around 90% (Samanek 1992; Samanek and Voriskova 1999). There are no reported data
for mortality or survival that differentiate by sex or race/ethnicity.
Aortic Valve Atresia
Aortic valve atresia is the absence of the aortic valve, prohibiting blood flow from
the heart to the body. Babies with aortic valve atresia survive only when patent ductus
arteriosus persists. Aortic valve atresia can be associated with hypoplastic left heart
syndrome, a complex condition characterized by an undeveloped left side of the heart,
including the aorta, left ventricle (a defect called hypoplastic left ventricle), and mitral
valve (defects referred to as mitral valve atresia or mitral valve stenosis).
Although some studies have findings for aortic valve stenosis and aortic valve
atresia/stenosis, there is a lack of information on disparity by sex or race/ethnicity
(Table 1).
METHODS
Study Design and Data Source
We conducted a retrospective cohort study of 219 infants with congenital aortic
valve atresia and 300 infants with aortic valve stenosis born in Texas between January 1,
1996 and December 31, 2007. Data was obtained from the Texas Birth Defects Registry
(TBDR), which is maintained by the Birth Defects Epidemiology and Surveillance
Branch of the Texas Department of State Health Services. In the TBDR population-based
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active surveillance system TBDR personnel review medical records to identify infants
diagnosed within the first year after birth with structural and chromosomal birth defects.
The TBDR surveillance began in 1995, and since 1999 data have been collected for all
births in the state of Texas. TBDR data are death-to-birth matched by the Texas Vital
Statistics Unit using decedent name, date of death and date of birth, mother’s first and
maiden and/or current last names.
The TBDR utilizes six-digit birth defect coding that has evolved through British
Pediatric Association (BPA) extension of the International Classification of Disease,
ninth revision clinical modification diagnostic codes (ICD-9 codes). Our study used data
coded according to the June 29, 2007 revision of TBDR’s BPA coding system.
Study Population
The study population included all live-born singleton infants with aortic valve
atresia or aortic valve stenosis (BPA Codes 746.480 and 746.300) born in Texas between
January 1, 1996 and December 31, 2007 to NH white, NH black, or Hispanic women of
any age. Aortic valve atresia and aortic valve stenosis cases with co-occurring heart
defects (BPA Codes 745.000 through 747.490) were considered for inclusion in our study
(Appendix A). However, cases associated with complex defects such as trisomies or
syndromes (except for hypoplastic left heart syndrome) were excluded from our study.
All cases were reviewed by a pediatric cardiologist, Dr. David E. Fixler, M.D., and aortic
valve atresia cases were included only if at least one of the following heart defects was
co-occurring: hypoplastic left heart syndrome (BPA Code 746.700), mitral valve stenosis
(BPA Code 746.500), mitral valve atresia (BPA Code 746.505), or hypoplastic left
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ventricle (BPA Code 746.881). Aortic valve stenosis cases were selected based on review
of these cases and their co-occurring heart defects.
Covariates
We used infant and maternal covariate information obtained by the TBDR from
birth certificate and medical records. We included infant sex, and maternal race/ethnicity
based on maternal self-report. Gestational age categorized as term (≥37 completed
weeks) or pre-term (<37 weeks) was included; gestational age was based on last
menstrual period or clinical estimate of gestation from medical records was substituted
when last menstrual period data were missing. Consistent with published literature, we
included birth weight categorized as normal (≥2500 grams), low (1500-2499 grams), or
very low (<1500 grams), as recorded on birth certificates (CDC 1990; Alexander, Kogan
et al. 2003; Nembhard 2011). Also consistent with literature, gestational age and birth
weight were included as a combination variable with six categories: <37 weeks and
<1500 grams; <37 weeks and 1500-2499 grams; <37 weeks and ≥2500 grams; ≥37 weeks
and <1500 grams; ≥37 weeks and 1500-2499 grams; and ≥37 weeks and ≥2500 grams
(Bol, Collins et al. 2006; Nembhard 2011). Maternal age categorized as <20 years, 20-29
years, 30-39 years, and 40+ years and maternal education categorized as high school (12
years), <high school, or >high school were also included. Number of co-occurring birth
defects was also included in the analyses as a continuous variable.
Data Analysis
Descriptive statistics were calculated for main study variables and covariates. We
calculated survival time using date of birth and date of death for deceased infants. When
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TBDR data did not have a date of death recorded, infants were censored at the end of the
study period, December 31, 2008.
Early childhood survival was estimated for children with each defect using the
Kaplan-Meier method. Kaplan-Meier survival curves were computed to compare survival
estimates by infant sex, and maternal race/ethnicity, and tested the difference between the
curves using the log-rank test.
Unadjusted and adjusted hazard ratios were calculated for mortality using Cox
proportional hazard regression models. The adjusted hazard ratios were computed using a
final regression model developed by backward selection method, removing variables with
less than 10% effect on the hazard ratio. The models for infant sex and maternal
race/ethnicity stratified by sex used females and NH whites as the reference groups. The
proportional hazards assumption was tested to ensure the assumption was met; we
inspected the proportionality by including time-dependent covariates in the model and
testing for their significance. Variables included in the final model were: maternal age,
maternal education, birth weight/gestational age, and number of defects. Although not all
variables had a major effect on the adjusted hazard ratios (i.e., changing the hazard ratio
by 10% or more), all of the variables included in the final model are biologically
important based on published literature. Results were considered statistically significant
if the 95% confidence interval excluded 1 or P<0.05. Calculations were performed using
SAS 9.2 for Kaplan-Meier survival estimates and Cox proportional hazards regression
models, and Stata Release 12 for Kaplan-Meier survival plots.
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Protection of Human Subjects
The study was conducted with the approval of the University of South Florida
Institutional Review Board (IRB), and the Texas Department of State Health Services.
Power and Sample Size
The formula used to estimate power for this study is an extension of Schoenfeld’s
sample-size formula for the proportional-hazards regression model, solved for power (1β) (Hipwell, Strachan et al. 2000; Shechter, Sharir et al. 2000):

(z1-α/2 + z1-β)2
N = _____________________
P (1-R2) σ2 B2

Where N is the sample size; z1-α/2 and z1-β are standard normal deviates at a twosided significance level α and power (1-β); P is the overall event rate or proportion of
non-censored participants; R2 is the effect size of covariates on the variable of interest; σ
is the standard deviation of the variable of interest; and B is the effect size (log of the
hazard ratio).
We calculated the power to detect hazard ratios of 1.5 and 3.0; the significance
level, alpha, for our study was 0.05. Since our associations indicate risk or protective
exposures, two sided hypotheses were tested. Standard deviation values of 0.5 and 0.7
were used to show a range of possibilities; the influence of covariates on the outcome, R2
was estimated at 0.15. Based on the study data, estimates of study power were calculated
based on three potential scenarios: 1) an event (death) rate of 5%, 2) an event rate of
10%, and 3) an event rate of 40%.
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The results of these calculations are presented in Appendix B. Since our study
size was fairly small for some of our stratified groups, our ability to observe statistically
significant results may be limited.
RESULTS
Aortic Valve Atresia
Descriptive statistics for infants born with aortic valve atresia are provided in
Table 2. The total number of aortic valve atresia cases in our study was 219 and included
89 NH white, 23 NH black, and 107 Hispanic children. Of these, 112 (51.1%) children
were alive at the end of our study and 107 (48.9%) were deceased. More than half
(52.2%) of the NH black children with aortic valve atresia died during the study period
while fewer than half of the Hispanic (48.6%) or NH white (48.3%) children died.
Approximately 80.4% of surviving children and 71.0% of deceased children were born
full term (≥37 weeks) and at normal birth weight (≥2500 grams). There were
considerably more males (62.6%) than females (37.4%) with aortic valve atresia.
Survival and Risk of Childhood Mortality by Infant Sex
Kaplan-Meier estimates, hazard ratios, and 95% confidence intervals are
presented in Table 3. Early childhood survival for males (55.0%) with aortic valve atresia
was significantly higher than for females (41.5%, P = 0.0451). After adjusting for
covariates, there was no statistically significant difference in early childhood mortality
between males and females with aortic valve atresia (HR 0.89; 95% CI 0.59-1.35;
P=0.584).
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Survival by Maternal Race/Ethnicity and Infant Sex
Kaplan-Meier estimates for children with aortic valve atresia are presented in
Table 4, and survival curves are presented in Figure 2. The estimated survival for
children was not significantly different for NH white (50.3%), NH black (47.4%), and
Hispanic (50.2%) children (P=0.9956); NH black males (35.7%), NH white males
(56.6%), and Hispanic (58.2%) males (P=0.3707); or NH black females (64.8%), NH
white females (39.4%), and Hispanic (38.1%) females (P=0.3160).
Risk of Childhood Mortality by Maternal Race/Ethnicity and Infant Sex
Hazard ratios and CI for early childhood mortality in children with aortic valve
atresia are presented in Table 5. After adjusting for covariates, NH black (HR 1.13; CI
0.58-2.22; P=0.7241) and Hispanic (HR 0.88; CI 0.57-1.38; P=0.5846) infants born with
aortic valve atresia do not have significantly different early childhood mortality than NH
white infants. Early childhood mortality was not statistically different in NH black
females (HR 0.33; CI 0.09-1.18; P=0.0886) or Hispanic females (HR 0.95; CI 0.47-1.94;
P=0.8886) compared to NH white females. NH black males (HR 1.95; CI 0.83-4.59;
P=0.1283) or Hispanic males (HR 0.50; CI 0.50-1.73; P=0.8604), did not have
statistically different early childhood mortality compared to NH white males.
Aortic Valve Stenosis
Descriptive statistics for infants born with aortic valve stenosis are provided in
Table 6. The study included 300 aortic valve stenosis cases: 145 NH white, 14 NH black,
and 141 Hispanic children. Of these, 268 (89.3%) were alive at the end of our study and
32 (10.7%) were deceased. Approximately 77.6% of surviving children and 56.3% of
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deceased children were born full term (≥37 weeks) and at normal birth weight (≥2500
grams). There were considerably more males (68.7%) than females (31.3%) with aortic
valve stenosis; however, of the deceased children approximately 46.9% were female.
Survival and Risk of Childhood Mortality by Infant Sex
Kaplan-Meier estimates, hazard ratios, and 95% confidence intervals are
presented in Table 3. Early childhood survival for males (91.6%) with aortic valve
stenosis was significantly higher than for females (82.5%, P=0.0492). After adjusting for
covariates, there was no statistically significant difference in early childhood mortality
between males and females with aortic valve stenosis (HR 0.80; 95% CI 0.37-1.73;
P=0.5748).
Survival by Maternal Race/Ethnicity and Infant Sex
The Kaplan-Meier estimates for children with aortic valve stenosis are presented
in Table 4, and Kaplan-Meier survival curves are presented in Figure 3. The estimated
survival for children was not significantly different for NH white (89.4%), NH black
(92.9%), and Hispanic (87.82%) children (P=0.8852); NH white males (91.9%) and
Hispanic (90.5%) males (P=0.6236); or NH black females (83.3%), NH white females
(83.3%), and Hispanic (81.6%) females (P=0.9625).
Risk of Childhood Mortality by Maternal Race/Ethnicity and Infant Sex
The Cox proportional hazards regression model results for children with aortic
valve stenosis adjusted for covariates are presented in Table 5. NH black (HR 0.40; CI
0.05-3.23; P=0.386) and Hispanic (HR 0.51; CI 0.20-1.28; P=0.1493) infants born with
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aortic valve stenosis do not have significantly lower risk for early childhood mortality
than NH white infants.
Cox proportional hazards model results by maternal race/ethnicity stratified by
infant sex and adjusted for covariates are presented in Table 5. Risk of early childhood
mortality was not statistically different in NH black females (HR 0.94; CI 0.09-9.75;
P=0.9608) or Hispanic females (HR 0.25; CI 0.06-1.14; P=0.0728) compared to NH
white females, or NH black males (HR undefined) and Hispanic males (HR 0.91; CI
0.26-3.22; P=0.8843) compared to NH white males with aortic valve stenosis.
DISCUSSION
We investigated 219 cases of aortic valve atresia and 300 cases of aortic valve
stenosis and for each defect we found males had higher early childhood survival than
females. After adjusting for covariates, we did not observe statistically significant
differences in early childhood mortality.
Aortic valve atresia has not previously been studied as a defect isolated from
aortic valve stenosis. Aortic valve atresia inclusion criteria for our study considered cases
only if at least one of the following defects was co-occurring: hypoplastic left heart
syndrome, mitral valve stenosis, mitral valve atresia, or hypoplastic left ventricle. As
such, we did not investigate aortic valve atresia as an isolated defect since clinically this
defect does not occur unless it is part of other malformations of the heart. For this reason,
our results for aortic valve atresia may not be directly comparable to findings of previous
studies.
Previous investigations have reported 1-year survival probabilities of 91 % (CI
89-92) (Samanek 1992) and 90% (CI 87-93) (Samanek and Voriskova 1999) for aortic
21

valve stenosis; our Kaplan-Meier survival curves for males do not conflict with these
findings, but females’ survival in the first year are below 90%, particularly for NH black
and NH white females in our study.
We found infant sex differences in the pattern of survival for our study period.
However, when considering the confounding influence of covariates, we did not see
differences in the risk of early childhood mortality. The variables with most influence on
the final regression model were birth weight/gestational age and number of co-occurring
defects.
Sex disparities in early childhood survival indicate genetics may influence
survival outcomes. Our study did not evaluate paternal variables such as paternal
race/ethnicity. We also did not investigate maternal or paternal environmental factors,
family history of congenital heart valve defects, or severity of defects. The possibility
exists that there are unidentified factors that explain the sex disparities in early childhood
survival for children with congenital aortic valve defects.
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Figure 2. Early childhood Kaplan-Meier survival curves for infants with aortic valve atresia
by infant sex and maternal race/ethnicity, Texas Birth Defects Registry, 1996-2008
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Figure 3. Early childhood Kaplan-Meier survival curves for infants with aortic valve stenosis
by infant sex and maternal race/ethnicity, Texas Birth Defects Registry, 1996-2008
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Fixler et al. 1993

Correa-Villasenor
et al. 1991
Botto et al. 2001

Nembhard et al.
2010

Nembhard, Wang et
al. 2010

Pradat et al. 2003

Nembhard et al.
2010

Ferencz et al. 1985

Author

Lower prevalence of AVS in MexicanAmericans (M-A) than whites

Study Population
Observation
Prevalence Per 10,000 Births
Baltimore-Washington Infant Study of 664 infants born in the
AVS
study area between 1981 and 1982 and diagnosed with
congenital heart disease.
Texas Birth Defects Registry data for 48,391 singleton infants
AVA/S in Hispanics
born between January 1 and December 31, 1996 and
AVA/S in Non-Hispanic Blacks
diagnosed with major birth defects.
AVA/S in Non-Hispanic Whites
California, Sweden and France birth defect registry data for
AVS in Asians
12,932 infants born between 1981 and 1992 with congenital
AVS in Blacks
heart defects.
AVS in Hispanics
AVS in Whites
Prevalence Comparisons for Race/Ethnicity
Florida Birth Defects Registry data for 16,788 singleton
Lower AVA/S rates in non-Hispanic
infants diagnosed with congenital heart defects, born between
black males than non-Hispanic white
1998 and 2003.
males
Lower AVA/S rates in non-Hispanic
black males than Hispanic males
Texas Birth Defects Registry data for 48,391 singleton infants
Lower AVA/S rates in non-Hispanic
born between January 1 and December 31, 1996 and
blacks than non-Hispanic whites
diagnosed with major birth defects.
Lower AVA/S in Hispanics than nonHispanic whites
Baltimore-Washington Infant Study of 2,087 infants with
Higher odds of AVS in whites than
cardiovascular malformations between 1981 and 1987.
blacks
Metropolitan Atlanta Congenital Defects Program data for
Lower AVS rate in blacks than whites
5,813 infants with major congenital heart defects born
between 1968 and 1997.
Dallas County, Texas data for 2,509 infants with congenital
Lower AVS rate in blacks than whites
heart disease born between 1971 and 1984.

Table 1. Descriptive epidemiology of aortic valve defects from published studies, 1985-2010

PR Blacks=0.07/1,000
PR Whites=0.4/1,000
(p<0.005)
PR M/A=0.20/1,000
PR Whites=0.4/1,000
(p<0.05)

RR=0.38 (0.22-0.64)

OR=3.6 (1.7-7.6)

RR=0.53 (0.28-0.97)

RR=0.46 (0.24-0.89)

RR=0.32 (0.12-0.89)

RR=0.34 (0.13-0.94)

1.03 (0.72-1.51)
0.89 (0.59-1.36)
1.95 (1.68-2.40)
0.94 (0.55-1.51)
0.61 (0.29-1.12)
0.81 (0.63-1.02)
1.39 (1.17-1.65)

0.81 (not reported)

Estimate (95% CI)

26

OR – Odds Ratio
RR – Rate Ratio

Samanek and
Voriskova 1999

Samanek 1992

Samanek 1994

Lubinsky 1997

Lary and Paulozzi
2001

Forrester and Merz
2004
Pradat et al. 2003

McBride et al. 2005

Carmichael et al.
2004

Author

Study Population
Observation
Estimate (95% CI)
Prevalence Comparisons for Race/Ethnicity, continued
California Birth Defects Monitoring Program surveillance data
Lower risk for AVS in foreign-born
for 2,234,846 infants and fetuses born between 1989 and 1997
Hispanics than US-born Hispanics,
ARR=0.7 (0.6-0.8)
with congenital malformations.
African-Americans or whites
Prevalence by Sex
Texas Birth Defects Registry data for 499 infants with left
Higher prevalence of AVS in males
PRR=2.71 (1.70-4.31)
ventricular outflow tract malformations (aortic valve stenosis,
coarctation of the aorta, and hypoplastic left heart syndrome)
born between 1999 and 2001.
Hawaii Birth Defects Program data for 5,010 infants with
Higher rate of AVS in males
RR=2.52 (1.61-3.75)
congenital heart defects born between 1986 and 1999.
California, Sweden and France birth defect registry data for
Higher prevalence risk of AVS in
Ratio of males to
12,932 infants born between 1981 and 1992 with congenital heart
males
females= 2.41
defects.
(1.84-3.25)
Metropolitan Atlanta Congenital Defects Program data for
Higher risk of AVS in males
RR=1.51 (1.11-2.07)
28,965 infants born between 1968 and 1995 with at least one
major birth defect.
Meta-analysis of sex biased congenital anomalies findings from
Aortic valve anomalies diagnosed in
76% in males
studies published between 1967 and 1993.
males more frequently than in
24% in females
females
(CI not reported)
4,409 children born in Bohemia between 1977 and 1984 with
Higher ratio of AVS in boys
Boy to Girl
congenital heart malformations.
Ratio=1.95:1
Survival Percent
946 Bohemian children with congenital heart disease who died
AVS 1-year survival rate
91% (89-92)
before they were 15 years of age; data were collected between
1952 and 1979.
5,030 children born in Bohemia between 1980 and 1990 with
AVS 1-year survival rate
90% (87-93)
congenital heart disease. Children were followed until age 15, or
until their death before reaching age 15.
ARR – Adjusted Relative Risk
PRR – Prevalence Relative Risk
AVS – Aortic Valve Stenosis
PR – Prevalence Rate
AVA/AVS – Aortic Valve Atresia/Stenosis
M-A – Mexican-American
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Due to rounding effect, percentages may not total 100.0%.

Table 2. Descriptive statistics for characteristics of infants with aortic valve atresia and their birth mothers, Texas Birth Defects Registry data for
children born 1996 to 2007
Non-Hispanic White
Non-Hispanic Black
Hispanic
Total
(n=89)
(n=23)
(n=107)
(n=219)
Characteristic
Deceased
Deceased
Deceased
Deceased
Alive
Alive
Alive
Alive
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
Infants
46
43
11
12
55
52
112
107
Sex
Male
33 (71.7)
23 (53.5)
5 (45.5)
9 (75.0)
39 (70.9)
28 (53.8)
77 (68.8)
60 (56.1)
Female
13 (28.3)
20 (46.5)
6 (54.5)
3 (25.0)
16 (29.1)
24 (46.2)
35 (31.3)
47 (43.9)
Birth weight/gestational age
< 37 wk < 1500 grams
0 (0.0)
2 (4.7)
0 (0.0)
0 (0.0)
0 (0.0)
5 (9.6)
0 (0.0)
7 (6.5)
< 37 wk 1500-2499 grams
6 (13.0)
3 (7.0)
2 (18.2)
1 (8.3)
4 (7.3)
5 (9.6)
12 (10.7)
9 (8.4)
< 37 wk ≥ 2500 grams
2 (4.3)
3 (7.0)
0 (0.0)
0 (0.0)
7 (12.7)
6 (11.5)
9 (8.0)
9 (8.4)
≥ 37 wk < 1500 grams
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
≥ 37 wk 1500-2499 grams
0 (0.0)
4 (9.3)
0 (0.0)
0 (0.0)
1 (1.8)
2 (3.8)
1 (0.9)
6 (5.6)
≥ 37 wk ≥ 2500 grams
38 (82.6)
31 (72.1)
9 (81.8)
11 (91.7)
43 (78.2)
34 (65.4)
90 (80.4)
76 (71.0)
Number of Defects - Males
Isolated
0
0
0
0
0
0
0
0
≤5
12 (36.4)
3 (13.0)
1 (20.0)
1 (11.1)
7 (17.9)
9 (32.1)
20 (26.0)
13 (21.7)
>5
21 (63.6)
20 (87.0)
4 (80.0)
8 (88.9)
32 (82.1)
19 (67.9)
57 (74.0)
47 (78.3)
Number of Defects - Females
Isolated
0
0
0
0
0
0
0
0
≤5
4 (30.8)
4 (20.0)
3 (50.0)
0 (0.0)
3 (18.8)
5 (20.8)
10 (28.6)
9 (19.1)
>5
9 (69.2)
16 (80.0)
3 (50.0)
3 (100.0)
13 (81.3)
19 (79.2)
25 (71.4)
38 (80.9)
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Table 2. Descriptive statistics for characteristics of infants with aortic valve atresia and their birth mothers, Texas Birth Defects Registry data for
children born 1996 to 2007
Non-Hispanic White
Non-Hispanic Black
Hispanic
Total
(n=89)
(n=23)
(n=107)
(n=219)
Characteristic
Deceased
Deceased
Deceased
Deceased
Alive
Alive
Alive
Alive
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
Mothers
Maternal Age (years)
< 20
1 (2.2)
1 (2.3)
4 (36.4)
3 (25.0)
11 (20.0)
7 (13.5)
16 (14.3)
11 (10.3)
20-29
26 (56.5)
27 (62.8)
6 (54.5)
6 (50.0)
33 (60.0)
32 (61.5)
65 (58.0)
65 (60.7)
30-39
18 (39.1)
13 (30.2)
1 (0.9)
3 (25.0)
10 (18.2)
9 (17.3)
29 (25.9)
25 (23.4)
> 40
1 (2.2)
2 (4.7)
0 (0.0)
0 (0.0)
1 (1.8)
4 (7.7)
2 (1.8)
6 (5.6)
Maternal Education
< High School
3 (6.5)
3 (7.0)
1 (9.0)
2 (16.7)
13 (23.6)
19 (36.5)
17 (15.2)
24 (22.4)
High School
7 (15.2)
13 (30.2)
4 (36.4)
3 (25.0)
12 (21.8)
15 (28.8)
23 (20.5)
31 (29.0)
> High School
15 (32.6)
12 (27.9)
1 (9.0)
1 (8.3)
6 (10.9)
3 (5.8)
22 (19.6)
16 (15.0)
Missing
21 (45.7)
15 (34.9)
5 (45.5)
6 (50.0)
24 (43.6)
15 (28.8)
50 (44.6)
36 (33.6)

29

79

Aortic Valve Stenosis

15

47

Deceased
n

82.5 (72.1-89.4)

41.5 (30.5-52.2)

Estimate
(95% CI)

189

77

Alive
n

17

60

Deceased
n

91.6 (86.8-94.7)

55.0 (46.0-63.2)

K-M Estimate
(95% CI)
*

0.89 (0.59-1.35)
0.80 (0.37-1.73)

0.0451 †
0.0492 †

*

†

Adjusted for maternal age, maternal education, birth weight/gestational age, infant sex, number of birth defects.

Statistically Significant at P<0.05

Adjusted HR (95% CI)

P value †

Study period 1996 to 2008; Kaplan-Meier estimate of study endpoint (December 31, 2008) survival probability.
CI - Confidence Interval
KM - Kaplan-Meier
HR - Hazard Ratio

35

Alive
n

Aortic Valve Atresia

Defect

0.5748

0.5840

P value †

Table 3. Kaplan-Meier (KM) survival estimates with 95% confidence intervals (CIs) and Cox proportional hazard ratios (HRs) for children with
congenital aortic valve defects using infant sex as a risk factor, Texas Birth Defects Registry data for children born 1996 to 2007
Female (Reference Group)
Male

30

46
13
33
125
35
95

43
20
23
15
7
8

50.3 (39.2-60.5)
39.4 (23.1-55.4)
56.6 (41.8-68.9)
89.4 (83.0-93.5)
83.3 (68.2-91.7)
91.9 (84.4-95.9)

11
6
5
13
5
8

12
3
9
1
1
0

47.4 (26.3-65.9)
64.8 (25.3-87.2)
35.7 (13.0-59.4)
92.9 (59.1-99.0)
83.3 (27.3-97.5)
undefined

55
16
39
120
39
86

52
24
28
16
7
9

†

Statistically Significant at P<0.05

KM - Kaplan-Meier

Study period 1996 to 2008; Kaplan-Meier estimate of the study endpoint (December 31, 2008) survival probability.
CI - Confidence Interval

Aortic Valve Atresia
Female
Male
Aortic Valve Stenosis
Female
Male

50.2 (40.0-59.5)
38.1 (22.7-53.2)
58.2 (45.5-68.9)
87.8 (80.6-92.4)
81.6 (63.6-91.3)
90.5 (82.6-95.0)

0.9956
0.3160
0.3707
0.8852
0.9625
0.6236

Table 4. Kaplan-Meier (KM) estimates with log-rank test and 95% confidence intervals (CIs) for survival in children with congenital aortic
valve defects using maternal race/ethnicity stratified by infant sex as risk factors, Texas Birth Defects Registry data for children born 1996 to
2007
Non-Hispanic White
Non-Hispanic Black
Hispanic
Survival
Survival
Survival
Defect
P value †
Alive Deceased
Alive Deceased
Alive Deceased
Estimate
Estimate
Estimate
n
n
n
n
n
n
(95% CI)
(95% CI)
(95% CI)
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145
42 (29.0)
103 (71.0)

Aortic Valve Stenosis
Female
Male

14
6 (42.9)
8 (57.1)

23
9 (39.1)
14 (60.9)

n (%) a
0.7241
0.0886
0.1283
0.3860
0.9608
--

1.13 (0.58-2.22) *
0.33 (0.09-1.18)
1.95 (0.83-4.59)
0.40 (0.05-3.23) *
0.94 (0.09-9.75)
undefined

Non-Hispanic Black
Adjusted HR
P value †
(95% CI) **

141
46 (32.6)
95 (67.4)

107
40 (37.4)
67 (62.6)

n (%) a

Study period 1996 to 2008
HR - Hazard Ratio
CI - Confidence Interval
a
Due to rounding effect, percentages may not total 100.0%.
† Statistically Significant at P<0.05
*
Adjusted for maternal age, maternal education, birth weight/gestational age, infant sex, number of birth defects.
**
Adjusted for maternal age, maternal education, birth weight/gestational age, number of birth defects; stratified by sex.

89
33 (37.1)
56 (62.9)

n (%) a

Aortic Valve Atresia
Female
Male

Defect

Non-Hispanic White
(Reference Group)

0.5846
0.8886
0.8604
0.1493
0.0728
0.8843

0.51 (0.20-1.28) *
0.25 (0.06-1.14)
0.91 (0.26-3.22)

P value †

0.88 (0.57-1.38) *
0.95 (0.47-1.94)
0.95 (0.50-1.73)

Hispanic
Adjusted HR
(95% CI) **

Table 5. Cox-proportional hazards regression model data for risk of mortality in children with congenital aortic valve defects using maternal
race/ethnicity by infant sex as a risk factor, Texas Birth Defects Registry data for children born 1996 to 2007
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a

Due to rounding effect, percentages may not total 100.0%.

Table 6. Descriptive statistics for characteristics of infants with aortic valve stenosis and their birth mothers, Texas Birth Defects Registry data for
children born 1996 to 2007
Non-Hispanic White
Non-Hispanic Black
Hispanic
Total
(n=145)
(n=14)
(n=141)
(n=300)
Characteristic
Deceased
Deceased
Deceased
Deceased
Alive
Alive
Alive
Alive
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
Infants
130
15
13
1
125
16
268
32
Sex
Male
95 (73.1)
8 (53.3)
8 (61.5)
0 (0.0)
86 (68.8)
9 (56.3)
189 (70.5)
17 (53.1)
Female
35 (26.9)
7 (46.7)
5 (38.5)
1 (100.0)
39 (31.2)
7 (43.8)
79 (29.5)
15 (46.9)
Birth weight/gestational age
< 37 wk < 1500 grams
4 (3.1)
2 (13.3)
0 (0.0)
0 (0.0)
5 (4.0)
1 (6.3)
9 (3.4)
3 (9.4)
< 37 wk 1500-2499 grams
5 (3.8)
2 (13.3)
3 (23.1)
0 (0.0)
10 (8.0)
5 (31.3)
18 (6.7)
7 (21.9)
< 37 wk ≥ 2500 grams
13 (10.0)
0 (0.0)
1 (7.7)
0 (0.0)
9 (7.2)
1 (6.3)
23 (8.6)
1 (3.1)
≥ 37 wk < 1500 grams
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
≥ 37 wk 1500-2499 grams
2 (1.5)
2 (13.3)
1 (7.7)
0 (0.0)
7 (5.6)
1 (6.3)
10 (3.7)
3 (9.4)
≥ 37 wk ≥ 2500 grams
106 (81.5)
9 (60.0)
8 (61.5)
1 (100.0)
94 (75.2)
8 (50.0)
208 (77.6)
18 (56.3)
Number of Defects - Males
Isolated
3
0
0
0
2
0
5
0
≤5
57 (60.0)
1 (12.5)
4 (50.0)
0 (0.0)
60 (69.8)
3 (33.3)
121 (64.0)
4 (23.5)
>5
38 (40.0)
7 (87.5)
4 (50.0)
0 (0.0)
26 (30.2)
6 (66.7)
68 (36.0)
13 (76.5)
Number of Defects - Females
Isolated
2
0
0
0
1
0
3
0
≤5
21 (60.0)
2 (28.6)
2 (40.0)
0 (0.0)
20 (51.3)
1 (14.3)
43 (54.4)
3 (20.0)
>5
14 (40.0)
5 (71.4)
3 (60.0)
1 (100.0)
19 (48.7)
6 (85.7)
36 (45.6)
12 (80.0)
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a

Due to rounding effect, percentages may not total 100.0%.

Table 6. Descriptive statistics for characteristics of infants with aortic valve stenosis and their birth mothers, Texas Birth Defects Registry data for
children born 1996 to 2007
Non-Hispanic White
Non-Hispanic Black
Hispanic
Total
(n=145)
(n=14)
(n=141)
(n=300)
Characteristic
Deceased
Deceased
Deceased
Deceased
Alive
Alive
Alive
Alive
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
Mothers
Maternal Age (years)
< 20
10 (7.7)
2 (13.3)
2 (15.4)
0 (0.0)
22 (17.6)
2 (12.5)
34 (12.7)
4 (12.5)
20-29
72 (55.4)
8 (53.3)
5 (38.5)
1 (100.0)
63 (50.4)
7 (43.8)
140 (52.2)
16 (50.0)
30-39
47 (36.2)
5 (33.3)
5 (38.5)
0 (0.0)
36 (28.8)
6 (37.5)
88 (32.8)
11 (34.4)
> 40
1 (0.8)
0 (0.0)
1 (7.7)
0 (0.0)
4 (3.2)
1 (6.3)
6 (2.2)
1 (3.1)
Maternal Education
< High School
7 (5.4)
3 (20.0)
0 (0.0)
0 (0.0)
40 (32.0)
7 (43.8)
47 (17.5)
10 (31.3)
High School
23 (17.7)
3 (20.0)
3 (23.1)
0 (0.0)
31 (24.8)
1 (6.3)
57 (21.3)
4 (12.5)
> High School
55 (42.3)
4 (26.7)
3 (23.1)
0 (0.0)
14 (11.2)
2 (12.5)
72 (26.9)
6 (18.8)
Missing
45 (34.6)
5 (33.3)
7 (53.8)
1 (100.0)
40 (32.0)
6 (37.5)
92 (34.3)
12 (37.5)

CHAPTER 3:
DISPARITIES IN SURVIVAL AND MORTALITY AMONG INFANTS WITH
CONGENITAL PULMONARY VALVE DEFECTS BY MATERNAL
RACE/ETHNICITY AND INFANT SEX

ABSTRACT
Background: Little is known about racial/ethnic or infant sex differences contributing to
the survival and mortality outcomes of children with pulmonary valve atresia or
pulmonary valve stenosis.
Methods: We conducted a retrospective cohort study of 1561 singleton infants born to
Hispanic, Non-Hispanic (NH) white, and NH black women in Texas between January 1,
1996 and December 31, 2007 with congenital pulmonary valve defects. Using data
collected by the Texas Birth Defects Registry, we calculated Kaplan-Meier survival
estimates, Cox-proportional hazards regression hazard ratios (HR) and 95% confidence
intervals (CI) to determine, after adjusting for confounders, whether infant sex or
maternal race/ethnicity affects early childhood survival or risk of mortality for these
children.
Results: Early childhood mortality was greater in NH black than NH white children with
pulmonary valve atresia and hypoplastic right ventricle (HRV) (HR=2.93; CI 1.09-7.85;
P=0.0329); NH black males were at much greater risk of early childhood mortality than
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NH white males (HR=4.63; CI 1.12-19.19; P=0.0349) with pulmonary valve atresia and
HRV. Early childhood survival estimates for males (94.9%) with pulmonary valve
stenosis were slightly lower (P=0.0116) than females (97.1%), and early childhood
survival for NH black children (94.1%) and Hispanic (95.3%) children were lower than
NH white (97.8%) children with pulmonary valve stenosis (P=0.0340).
Conclusion: We observed infant sex and racial/ethnic disparities in survival and early
childhood mortality for infants born with pulmonary valve atresia with HRV and those
without HRV.
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INTRODUCTION
Birth defects are a primary cause of infant mortality and contribute more than half
of the reported hospitalization costs associated with birth defects in the United States
(Russo 2007). In order to improve the health and survival of infants and children, public
health researchers need to better understand risk factors associated with congenital heart
defects so that effective prevention and treatment programs can be developed and
implemented (Botto, Correa et al. 2001; Nembhard, Waller et al. 2001; Cleves, Ghaffar et
al. 2003; Nembhard, Salemi et al. 2007; Nembhard, Pathak et al. 2008; Nembhard,
Salemi et al. 2009; Fixler, Nembhard et al. 2010; Nembhard, Salemi et al. 2010). We
present our investigation of infant sex and maternal race/ethnicity risk factors
contributing to early childhood survival and risk of mortality for infants born with
pulmonary valve atresia or pulmonary valve stenosis.
Pulmonary Valve Stenosis
Pulmonary valve stenosis is a narrowing of the valve located between the right
ventricle and the pulmonary artery, restricting blood flow from the heart to the lungs. It is
an obstruction defect included in the broader category of right ventricular outflow tract
obstruction (RVOTO). Pulmonary valve stenosis is relatively common, and accounts for
approximately 10 percent of all children with congenital heart defects. Table 7 provides a
summary of study findings for pulmonary valve defects. As shown in the table, some
studies did not differentiate pulmonary valve stenosis from pulmonary valve atresia.
There are varied degrees of severity for pulmonary valve stenosis. In mild cases,
pulmonary valve stenosis usually does not require treatment, but in severe cases, infants
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are cyanotic at birth and eventually develop increasingly severe obstruction as he/she
grows.
Pulmonary valve stenosis is a major component of another complex congenital
heart defect – tetralogy of Fallot. There is a potential genetic contribution to risk of
pulmonary valve stenosis since familial occurrence has been reported and the defect is
associated with Algille syndrome and Noonan’s syndrome (Moller and Neal 1990).
The reported prevalence of pulmonary valve stenosis per 10,000 live births ranges
from 1.10 (95% CI 0.89-1.34) to 10.1 (95% CI 9.3-10.9) (Ferencz, Rubin et al. 1985;
Pradat, Francannet et al. 2003; Dadvand, Rankin et al. 2009) (Table 7). Racial/ethnic
disparity in pulmonary valve stenosis has been reported. Fewer cases of pulmonary valve
stenosis have been reported for whites compared to blacks (Odds Ratio=0.6; 95% CI 0.40.8) (Correa-Villasenor, McCarter et al. 1991). Nembhard, Wang et al. (2010) found
increased prevalence of pulmonary valve atresia/stenosis in NH black males, compared to
NH white males (Rate Ratio (RR)=1.72; 95% CI 1.30-2.29) and in NH black females,
compared to NH white females (RR=1.64; 95% CI 1.22-2.19). Another study found that
NH black infants had a higher prevalence rate of pulmonary valve atresia/stenosis than
NH white infants (RR=1.68; 95% CI 1.38-2.05) (Nembhard, Salemi et al. 2010).
However, since data for pulmonary valve atresia and stenosis were combined in these
studies.
Survival of infants born with pulmonary valve stenosis is high. It was reported as
having the highest first year survival of congenital heart defects studied in Arkansas birth
defects registry data for 1993 to 1998 (Cleves, Ghaffar et al. 2003). First-year survival for
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infants born with pulmonary valve stenosis is about 96 to 97% (Samanek 1992; Samanek
and Voriskova 1999).
A study using data from the Texas Birth Defects Registry (TBDR) found higher
risk of early childhood mortality in NH black (HR 2.60; CI 1.32-5.12; P=0.0058) and
Hispanic (HR 1.76; CI 1.06-2.91; P=0.0290) children compared to NH white children
with pulmonary valve atresia without ventricular septal defect (Nembhard, Salemi et al.
2011). There are no reported significant disparities for the risk of mortality for infants
with congenital pulmonary valve stenosis.
Pulmonary Valve Atresia
Pulmonary valve atresia is the absence of the pulmonary valve. Babies with
pulmonary valve atresia can survive if the ductus arteriosus does not close, which is
called patent ductus arteriosus. This defect sometimes occurs in conjunction with the
underdevelopment of the right ventricle, a heart defect referred to as hypoplasia of the
right ventricle. In other cases, hypoplasia of the right ventricle is absent. Pulmonary valve
atresia is commonly present in conjunction with another congenital heart defect,
ventricular septal defect, (an opening in the wall between the two heart ventricles).
Pulmonary valve atresia with intact ventricular septum is uncommon; it can be diagnosed
during the fetal stage (in utero) when pregnancy termination is an option. Pulmonary
valve atresia is also associated with another congenital heart defect, Ebstein’s anomaly.
Pulmonary valve atresia is also associated with DiGeorge syndrome, a genetic mutation
disease. Table 7 provides a summary of study findings for pulmonary valve defects. As
shown in the table, some studies did not differentiate pulmonary valve stenosis from
pulmonary valve atresia.
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The prevalence of pulmonary valve atresia per 10,000 live births ranges from 0.73
(95% CI 0.55-0.91) to 5.8 (Ferencz, Rubin et al. 1985; Pradat, Francannet et al. 2003).
Racial/ethnic disparity in pulmonary valve atresia has been reported. An excess of
pulmonary valve atresia was found in whites compared to blacks (Odds Ratio=2.5; 95%
CI 1.0-6.1) (Correa-Villasenor, McCarter et al. 1991). Also, as discussed for pulmonary
valve stenosis, Nembhard, Wang et al. (2010) and Nembhard, Salemi et al. (2010) found
racial/ethnic disparity in prevalence of pulmonary valve atresia/stenosis as a combined
defect category.
Survival of infants born with pulmonary valve atresia is low; the 1-year survival
for pulmonary valve atresia has been reported by Samanek and Voriskova (1999) as 19%
(95% CI 8-30) and Samanek (1992) as 30% (95% CI 12-47). There are no reported data
for survival by infant sex or maternal race/ethnicity or data on the risk of mortality for
pulmonary valve atresia.
METHODS
Study Design and Data Source
We conducted a retrospective cohort study of 238 infants with congenital
pulmonary valve atresia and 1,323 infants with pulmonary valve stenosis born in Texas
between January 1, 1996 and December 31, 2008. The source of data used in our study is
the Texas Birth Defects Registry (TBDR), maintained by the Birth Defects Epidemiology
and Surveillance Branch of the Texas Department of State Health Services. The TBDR
includes population-based data obtained by active surveillance; TBDR personnel review
medical records to identify infants diagnosed within the first year after birth with
structural and chromosomal birth defects. The TBDR surveillance began in 1995, and
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since 1999 data have been collected for all births in the state of Texas. TBDR data are
death-to-birth matched by the Texas Vital Statistics Unit using decedent name, date of
death and date of birth, mother’s first and maiden and/or current last names.
The TBDR utilizes six-digit birth defect coding that has evolved through British
Pediatric Association (BPA) extension of the International Classification of Disease,
ninth revision clinical modification diagnostic codes (ICD-9 codes).
Study Population
The study population included all live-born singleton infants with pulmonary
valve atresia or pulmonary valve stenosis (BPA Codes 746.000 and 746.010) born in
Texas between January 1, 1996 and December 31, 2008 to NH white, NH black, or
Hispanic women of any age. Pulmonary valve atresia and pulmonary valve stenosis cases
with co-occurring heart defects (BPA Codes 745.000 through 747.490) were considered
for inclusion in our study (Appendix A). However, cases associated with complex defects
such as trisomies or syndromes were excluded. For example, pulmonary valve atresia
associated with Ebstein’s anomaly or DiGeorge syndrome and pulmonary valve stenosis
associated tetralogy of Fallot, Algille syndrome, or Noonan’s syndrome were not
included in our study.
All cases were reviewed by a pediatric cardiologist (Dr. David Fixler, M.D.).
Pulmonary valve atresia cases were included and evaluated as two separate conditions: if
pulmonary valve atresia was co-occurring with hypoplastic right ventricle (HRV) (BPA
Code 746.882) and if pulmonary valve atresia was not accompanied by HRV. We did not
include or exclude cases of pulmonary valve atresia based on the presence or absence of
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ventricular septal defect. Pulmonary valve stenosis cases were selected based on review
of these cases and their co-occurring heart defects.
Covariates
We used infant and maternal covariate information obtained by the TBDR from
birth certificate and medical records. We included infant sex and maternal race/ethnicity
based on maternal self-report. Gestational age categorized as term (≥37 completed
weeks) or pre-term (<37 weeks) was included; gestational age was based on last
menstrual period or clinical estimate of gestation from medical records was substituted
when last menstrual period data were missing. Consistent with published literature, we
included birth weight categorized as normal (≥2500 grams), low (1500-2499 grams), or
very low (<1500 grams), as recorded on birth certificates (CDC 1990; Alexander, Kogan
et al. 2003; Nembhard 2011). Also consistent with literature, gestational age and birth
weight were included as a combination variable with six categories: <37 weeks and
<1500 grams; <37 weeks and 1500-2499 grams; <37 weeks and ≥2500 grams; ≥37 weeks
and <1500 grams; ≥37 weeks and 1500-2499 grams; and ≥37 weeks and ≥2500 grams
(Bol, Collins et al. 2006; Nembhard 2011). Maternal age categorized as <20 years, 20-29
years, 30-39 years, and 40+ years and maternal education categorized as high school (12
years), <high school, or >high school were also included. Number of co-occurring birth
defects was also included in the analysis as a continuous variable.
Data Analysis
Descriptive statistics were calculated for main study variables and covariates. We
calculated survival time using date of birth and date of death for deceased infants. When
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TBDR data did not have a date of death recorded, infants were censored at the end of the
study period, December 31, 2008.
Early childhood survival was estimated for children with each defect using the
Kaplan-Meier method. Kaplan-Meier survival curves were computed to compare survival
estimates by infant sex, and maternal race/ethnicity, and tested the difference between the
curves using the log-rank test.
Unadjusted and adjusted hazard ratios were calculated for mortality using Cox
proportional hazard regression models. The adjusted hazard ratios were computed using a
final regression model developed by backward selection method, removing variables with
less than 10% effect on the hazard ratio. The models for infant sex and maternal
race/ethnicity stratified by sex used females and NH whites as the reference groups. The
proportional hazards assumption was tested to ensure the assumption was met; we
inspected the proportionality by including time-dependent covariates in the model and
testing for their significance. Variables included in the final model were: maternal age,
maternal education, birth weight/gestational age, and number of defects. Although not all
variables had a major effect on the adjusted hazard ratios (i.e., changing the hazard ratio
by 10% or more), all of the variables included in the final model are biologically
important based on published literature. Results were considered statistically significant
if the 95% confidence interval excluded 1 or P<0.05. Calculations were performed using
the SAS 9.2 for Kaplan-Meier survival estimates and Cox proportional hazards regression
models, and Stata Release 12 for Kaplan-Meier survival plots.
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Protection of Human Subjects
The study was conducted with the approval of the University of South Florida
Institutional Review Board (IRB) and the Texas Department of State Health Services.
Power and Sample Size
The formula used to estimate power for this study is an extension of Schoenfeld’s
sample-size formula for the proportional-hazards regression model, solved for power (1β) (Hipwell, Strachan et al. 2000; Shechter, Sharir et al. 2000):

(z1-α/2 + z1-β)2
N = _____________________
P (1-R2) σ2 B2

Where N is the sample size; z1-α/2 and z1-β are standard normal deviates at a twosided significance level α and power (1-β); P is the overall event rate or proportion of
non-censored participants; R2 is the effect size of covariates on the variable of interest; σ
is the standard deviation of the variable of interest; and B is the effect size (log of the
hazard ratio).
We calculated the power to detect hazard ratios of 1.5 and 3.0; the significance
level, alpha, for our study was 0.05. Since our associations indicate risk or protective
exposures, two sided hypotheses were tested. Standard deviation values of 0.5 and 0.7
were used to show a range of possibilities; the influence of covariates on the outcome, R2
was estimated at 0.15. Based on the study data, estimates of study power were calculated
based on three potential scenarios: 1) an event (death) rate of 5%, 2) an event rate of
10%, and 3) an event rate of 40%.
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The results of these calculations are presented in Appendix B. Since our study
size was fairly small for some of our stratified groups, our ability to observe statistically
significant results may be limited.
RESULTS
Pulmonary Valve Atresia with HRV
Descriptive statistics for infants born with pulmonary valve atresia with HRV are
provided in Table 8. The total number of cases in our study was 124 and included 40 NH
white, 16 NH black, and 68 Hispanic children. Of these, 83 (66.9%) children were alive
at the end of our study and 41 (33.1%) were deceased. Approximately 79.5% of surviving
children and 56.1% of deceased children were born full term (≥37 weeks) and at normal
birth weight (≥2500 grams). There were more males (55.6%) than females (44.4%) with
pulmonary valve atresia and HRV.
Survival and Risk of Childhood Mortality by Infant Sex
Kaplan-Meier estimates, hazard ratios, and 95% CI are presented in Table 9.
Early childhood survival for males (68.9%) with pulmonary valve atresia and HRV was
not different from females (62.3%) (P = 0.4499), nor was there statistically significant
difference in early childhood mortality between males and females with pulmonary valve
atresia and HRV (HR 1.19; 95% CI 0.59-2.40; P=0.6333) after adjusting for potential
confounders.
Survival by Maternal Race/Ethnicity and Infant Sex
Kaplan-Meier estimates for children with pulmonary valve atresia and HRV are
presented in Table 10, and survival curves are presented in Figure 4. The estimated
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survival for NH black children (43.8%) was not significantly lower than NH white
(77.5%) and Hispanic (64.2%) children (P=0.1081). There were not statistically
significant differences in estimated survival for NH black males (44.4%) compared to
NH white males (75.0%) and Hispanic males (70.6%, P=0.2019), or for NH black
females (42.9%) and Hispanic females (57.3%) compared to NH white females (81.3%,
P=0.2547).
Risk of Childhood Mortality by Maternal Race/Ethnicity and Infant Sex
The Cox proportional hazards regression model results for risk of mortality in
children with pulmonary valve atresia and HRV, comparing NH blacks to the reference
group of NH whites adjusted for potential confounders and results for the model stratified
by sex are presented in Table 11. Based on the results of our study, NH black children
with pulmonary valve atresia and HRV have 193% higher risk of early childhood
mortality than NH white children with the same defect (HR 2.93; CI 1.09-7.85;
P=0.0329). Also shown in Table 11, this risk was due to the 363% higher risk of early
childhood mortality in NH black male children compared to NH white males (HR 4.63;
CI 1.12-19.18; P=0.0349), since NH black females with this defect do not have
significantly higher risk of early childhood mortality than NH white children (HR 1.42;
CI 0.27-7.57; P=0.6794).
The Cox proportional hazards model results by maternal race/ethnicity and by
maternal race/ethnicity stratified by sex for children with pulmonary valve atresia and
HRV, as presented in Table 11, do not show significant differences in risk of childhood
mortality in Hispanic children (HR 1.04; CI 0.44-2.44; P=0.9258), Hispanic females (HR

45

0.88; CI 0.21-3.76; P=0.86), or Hispanic males (HR 1.17; CI 0.36-3.83; P=0.7974),
compared to NH whites.
Pulmonary Valve Atresia without HRV
Descriptive statistics for characteristics of infants with pulmonary valve atresia
without HRV and their birth mothers are provided in Table 12. The total number of cases
in our study was 114 and included 41 NH white, 15 NH black, and 58 Hispanic children.
Of these, 60 (52.6%) children were alive at the end of our study and 54 (47.4%) were
deceased. Approximately 75% of surviving children and 63% of deceased children were
born full term and at normal birth weight. There were approximately as many males
(50.9%) as females (49.1%) that had pulmonary valve atresia without HRV.
Survival and Risk of Childhood Mortality by Infant Sex
Kaplan-Meier estimates, hazard ratios and 95% CI are presented in Table 9. Early
childhood survival for males (60.3%) with pulmonary valve atresia without HRV was
higher than females (44.3%), but not significantly (P = 0.1019). After adjusting for
covariates, there was no statistically significant difference in early childhood mortality
between males and females with pulmonary valve atresia without HRV (HR 0.77; 95%
CI 0.41-1.46; P=0.4267).
Survival by Maternal Race/Ethnicity and Infant Sex
Kaplan-Meier estimates for children with pulmonary valve atresia without HRV
are presented in Table 10, and survival curves are presented in Figure 5. The estimated
survival was not significantly different for NH black children (40.0%) and Hispanic
(48.3%) children compared to NH white children (62.4%, P=0.1767), NH black males
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(28.6%) and Hispanic males (57.1%) compared to NH white males (73.9%, P=0.1052), or
NH black females (50.0%) and Hispanic females (40.0%) compared to NH white females
(49.4%, P=0.5851).
Risk of Childhood Mortality by Maternal Race/Ethnicity and Infant Sex
Hazard ratios and CI for early childhood mortality in children with pulmonary
valve atresia without HRV are presented in Table 11. There was no statistical difference
in early childhood mortality in NH black (HR 2.32; CI 0.93-5.83; P=0.0729) and
Hispanic (HR 1.66; CI 0.80-3.45; P=0.1781) infants born with pulmonary valve atresia
without HRV compared to NH white infants. Stratifying by sex and adjusting for
covariates did not result in statistically different early childhood mortality in NH black
females (HR 1.75; CI 0.42-7.27; P=0.4393) or Hispanic females (HR 1.45; CI 0.57-3.68;
P=0.4385) compared to NH white females, or NH black males (HR 3.87; CI 0.96-15.57;
P=0.057) and Hispanic males (HR 2.68; CI 0.72-10.01; P=0.1416) compared to NH white
males.
Pulmonary Valve Stenosis
Descriptive statistics for infants born with pulmonary valve stenosis are provided
in Table 13. The total number of cases in our study was 1323 and included 517 NH
white, 169 NH black, and 637 Hispanic children. Of these, 1275 (96.4%) children were
alive at the end of our study and 48 (3.6%) were deceased. Approximately 70% of
surviving children and 39.6% of deceased children were born full term (≥37 weeks) and
at normal birth weight (≥2500 grams); however, approximately 47.9% of deceased
children were born pre-term (<37 weeks) and at low (1500-2499) or very low (<1500
grams) birth weight. There were fewer males (44.9%) than females (55.1%) that had
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pulmonary valve stenosis; however, approximately 62.5% of the deceased cases were
males.
Survival and Risk of Childhood Mortality by Infant Sex
Kaplan-Meier estimates, hazard ratios, and 95% confidence intervals are
presented in Table 9. Early childhood survival for males (94.9%) with pulmonary valve
stenosis was significantly lower (P=0.0116) than females (97.1%). After adjusting for
covariates, there was no statistically significant difference in early childhood mortality
between males and females with pulmonary valve stenosis (HR 1.74; 95% CI 0.94-3.21;
P=0.0768).
Survival by Maternal Race/Ethnicity and Infant Sex
Kaplan-Meier estimates for children with pulmonary valve stenosis are presented
in Table 10, and survival curves are presented in Figure 7. The estimated survival for NH
black children (94.1%) and Hispanic (95.3%) children was statistically lower than NH
white children (97.8%), (P=0.034). However, survival was not statistically different for
NH black males (93.0%), Hispanic males (93.9%), and NH white males (97.2%,
P=0.1661), or NH black females (94.9%), Hispanic females (96.70%), and NH white
females (98.2%, P=0.1357).
Risk of Childhood Mortality by Maternal Race/Ethnicity and Infant Sex
Hazard ratios and CI for early childhood mortality in children with pulmonary
valve stenosis are presented in Table 11. NH black children (HR 1.90; CI 0.78-4.62;
P=0.1565) and Hispanic children (HR 0.89; CI 0.40-1.99; P=0.7806) born with
pulmonary valve stenosis did not have significantly different risk of early childhood
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mortality than NH white infants. After stratifying by infant sex and adjusting for
covariates, early childhood mortality was higher but not statistically significant in NH
black females (HR 2.34; CI 0.61-8.91; P=0.2138) and lower but not significant in
Hispanic females (HR 0.66; CI 0.18-2.46; P=0.533) compared to NH white females.
Differences in males were also not statistically significant: NH black males (HR 1.71; CI
0.50-5.90; P=0.3962), and Hispanic males (HR 1.19; CI 0.43-3.32; P=0.7424), when
compared to NH white males.
DISCUSSION
We investigated 124 cases of pulmonary valve atresia with HRV, 114 cases of
pulmonary valve atresia without HRV, and 1323 cases of pulmonary valve stenosis. We
found that among children with pulmonary valve atresia with HRV, NH blacks had
higher risk (193%) than NH whites and this risk was the result of NH black males having
considerably higher risk (363%) of early childhood mortality than NH white males. We
did not find differences by sex or race/ethnicity for children with pulmonary valve atresia
without HRV indicating the risk factors for children with this defect differ from those
affecting children with pulmonary valve atresia with HRV.
We found that males with pulmonary valve stenosis had lower early childhood
survival than females with this defect. We also found that early childhood survival for
children with aortic valve stenosis also varied by maternal race/ethnicity. NH white and
Hispanic females had fewer deaths in the first year of life than their male counterparts but
also had more deaths than males in subsequent years. After adjusting for confounders we
did not find significant differences in early childhood mortality for children with
pulmonary valve stenosis.
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We found infant sex and maternal race/ethnicity differences in the pattern of
survival for pulmonary valve stenosis during study period. However, when considering
the confounding influence of covariates, we did not find differences in the risk of early
childhood mortality for this defect. We found infant sex and maternal race/ethnicity
differences in early childhood mortality for children with pulmonary valve atresia and
HRV, but had no significant findings for children with pulmonary valve atresia without
HRV. The variables with most influence on the final regression models for were birth
weight/gestational age and number of co-occurring defects.
Sex disparities in early childhood survival indicate genetics may influence
survival. Our study did not evaluate paternal variables such as paternal race/ethnicity. We
also did not investigate maternal or paternal environmental factors, family history of
congenital heart valve defects, or severity of defects. The possibility exists that there are
unidentified factors that explain the sex disparities in early childhood survival for
children with congenital pulmonary valve defects.
Pulmonary valve atresia inclusion criteria for our study were unique: we
evaluated cases with HRV separately from cases without HRV. As discussed earlier and
summarized in Table 7, findings of infant sex and maternal race/ethnicity disparities in
the survival probability or risk of mortality in children with pulmonary valve defects have
not been reported. However, pulmonary valve atresia has not previously been studied in
the way we defined our defect, with or without HRV. Therefore, our results may not be
directly comparable to findings of previous studies.
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Figure 4. Early childhood Kaplan-Meier survival curves for infants with pulmonary valve
atresia and hypoplastic right ventricle by infant sex and maternal race/ethnicity,
Texas Birth Defects Registry, 1996-2008
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Figure 5. Early childhood Kaplan-Meier survival curves for infants with pulmonary valve
atresia without hypoplastic right ventricle by infant sex and maternal race/ethnicity,
Texas Birth Defects Registry, 1996-2008
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Figure 6. Early childhood Kaplan-Meier survival curves for infants with pulmonary valve
stenosis by infant sex and maternal race/ethnicity, Texas Birth Defects Registry, 1996-2008

0

Female, Non-Hispanic White

Infant Sex and Maternal Race/Ethnicity
Male, Non-Hispanic White

10

54

Correa-Villasenor et
al. 1991

Nembhard et al. 2010

Nembhard, Wang et al.
2010

Pradat et al. 2003

Ferencz et al. 1985

Dadvand et al. 2009

Nembhard et al. 2010

Author

Study Population
Observation
Prevalence Per 10,000 Births
Texas Birth Defects Registry data for 48,391 singleton infants
PVA/S in Hispanics
born between January 1 and December 31, 1996 and
PVA/S in Non-Hispanic Blacks
diagnosed with major birth defects.
PVA/S in Non-Hispanic Whites
Northern region of England population-based register of
PVS (North of England
5,715 livebirths, stillbirths, and terminations of pregnancy for
population)
fetal anomaly, between 1985 and 2003.
Baltimore-Washington Infant Study of 664 infants born in the
PVA
study area between 1981 and 1982 and diagnosed with
PVS
congenital heart disease.
California, Sweden and France birth defect registry data for
PVA in Asians
12,932 infants born between 1981 and 1992 with congenital
PVA in Blacks
heart defects.
PVA in Hispanics
PVA in Whites
PVS in Asians
PVS in Blacks
PVS in Hispanics
PVS in Whites
Prevalence Comparisons for Race/Ethnicity
Florida Birth Defects Registry data for 16,788 singleton
Higher PVA/S rates in noninfants diagnosed with congenital heart defects, born between
Hispanic black males than non1998 and 2003.
Hispanic white males
Higher PVA/S rates in nonHispanic black females than nonHispanic white females
Texas Birth Defects Registry data for 48,391 singleton infants
Higher PVA/S rates in nonborn between January 1 and December 31, 1996 and
Hispanic blacks than non-Hispanic
diagnosed with major birth defects.
whites
Baltimore-Washington Infant Study of 2,087 live births with
Lower odds for PVS in whites than
cardiovascular malformations between 1981 and 1987.
blacks
Higher odds for PVA in whites
than blacks

Table 7. Descriptive epidemiology of pulmonary valve defects from published studies, 1985-2011

OR=2.5 (1.0-6.1)

OR=0.6 (0.4-0.8)

RR=1.68 (1.38-2.05)

RR=1.64 (1.22-2.19)

RR=1.72 (1.30-2.29)

0.94 (0.55-1.51)
0.79 (0.42-1.35)
0.73 (0.55-0.91)
0.76 (0.59-0.93)
1.28 (0.81-1.92)
1.34 (0.84-2.02)
1.10 (0.89-1.34)
1.71 (1.46-1.98)

3.78 (not reported)

5.8 (not reported)

10.1 (9.3, 10.9)

8.91 (8.10-10.38)
14.73 (13.88-16.87)
8.78 (8.40-9.90)

Estimate (95% CI)
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Nembhard, Salemi et
al. 2011

RR – Rate Ratio
PVA – Pulmonary Valve Atresia

Risk of Mortality
Texas Birth Defects Registry data for 19.530 singleton infants
born between January 1, 1996 and December 31, 2003 and
diagnosed with congenital heart defects.

HR – Hazard Ratio
OR – Odds Ratio

Study Population

Author

Estimate (95% CI)

Increased risk of early childhood
mortality in Non-Hispanic Black
HR=2.60 (1.32-5.12)
children compared to NonP=0.0058
Hispanic White children.
Increased risk of early childhood
mortality in Hispanic children
HR=1.76 (1.06-2.91)
compared to Non-Hispanic White
P=0.0290
children.
PVS – Pulmonary Valve Stenosis
PVA/S – Pulmonary Valve Atresia/Stenosis

Observation

Table 7. Descriptive epidemiology of pulmonary valve defects from published studies, 1985-2011
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Due to rounding effect, percentages may not total 100.0%.

Table 8. Descriptive statistics for characteristics of infants with pulmonary valve atresia with hypoplastic right ventricle and their birth mothers,
Texas Birth Defects Registry data for children born 1996 to 2007
Non-Hispanic White
Non-Hispanic Black
Hispanic
Total
(n=40)
(n=16)
(n=68)
(n=124)
Characteristic
Deceased
Deceased
Deceased
Deceased
Alive
Alive
Alive
Alive
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
Infants
31
9
7
9
45
23
83
41
Sex
Male
18 (58.1)
6 (66.7)
4 (57.1)
5 (55.6)
26 (57.8)
10 (43.5)
48 (57.8)
21 (51.2)
Female
13 (41.9)
3 (33.3)
3 (42.9)
4 (44.4)
19 (42.2)
13 (56.5)
35 (42.2)
20 (48.8)
Birth weight/gestational age
< 37 wk < 1500 grams
0 (0.0)
1 (11.1)
0 (0.0)
0 (0.0)
0 (0.0)
3 (13.0)
0 (0.0)
4 (9.8)
< 37 wk 1500-2499 grams
3 (9.7)
1 (11.1)
0 (0.0)
0 (0.0)
4 (8.9)
4 (17.4)
7 (8.4)
5 (12.2)
< 37 wk ≥ 2500 grams
4 (12.9)
1 (11.1)
0 (0.0)
1 (11.1)
2 (4.4)
3 (13.0)
6 (7.2)
5 (12.2)
≥ 37 wk < 1500 grams
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
≥ 37 wk 1500-2499 grams
0 (0.0)
0 (0.0)
0 (0.0)
2 (22.2)
4 (8.9)
2 (8.7)
4 (4.8)
4 (9.8)
≥ 37 wk ≥ 2500 grams
24 (77.4)
6 (66.7)
7 (100.0)
6 (66.7)
35 (77.8)
11 (47.8)
66 (79.5)
23 (56.1)
Number of Defects - Males
Isolated
0
0
0
0
0
0
0
0
≤5
3 (16.7)
3 (50.0)
0 (0.0)
0 (0.0)
3 (11.5)
1 (10.0)
6 (12.5)
4 (19.0)
>5
15 (83.3)
3 (50.0)
4 (100.0)
5 (100.0)
23 (88.5)
9 (90.0)
42 (87.5)
17 (81.0)
Number of Defects - Females
Isolated
0
0
0
0
0
0
0
0
≤5
2 (15.4)
0 (0.0)
1 (33.3)
1 (33.3)
1 (5.3)
0 (0.0)
4 (11.4)
1 (5.0)
>5
11 (84.6)
3 (100.0)
2 (66.7)
3 (66.7)
18 (94.7)
13 (100.0)
31 (88.6)
19 (95.0)
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Table 8. Descriptive statistics for characteristics of infants with pulmonary valve atresia with hypoplastic right ventricle and their birth mothers,
Texas Birth Defects Registry data for children born 1996 to 2007
Non-Hispanic White
Non-Hispanic Black
Hispanic
Total
(n=40)
(n=16)
(n=68)
(n=124)
Characteristic
Deceased
Deceased
Deceased
Deceased
Alive
Alive
Alive
Alive
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
Mothers
Maternal Age (years)
< 20
5 (16.1)
1 (11.1)
1 (14.3)
0 (0.0)
7 (15.6)
4 (17.4)
13 (15.7)
5 (12.2)
20-29
17 (54.8)
4 (44.4)
5 (71.4)
6 (66.7)
24 (53.3)
14 (60.9)
46 (55.4)
24 (58.5)
30-39
7 (22.6)
4 (44.4)
1 (14.3)
3 (33.3)
14 (31.1)
5 (21.7)
22 (26.5)
12 (29.3)
> 40
2 (6.5)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
2 (2.4)
0 (0.0)
Maternal Education
< High School
4 (12.9)
1 (11.1)
2 (28.6)
0 (0.0)
11 (24.4)
9 (39.1)
17 (20.5)
10 (24.4)
High School
8 (25.8)
3 (33.3)
0 (0.0)
2 (22.2)
11 (24.4)
6 (26.1)
19 (22.9)
11 (26.8)
> High School
12 (38.7)
3 (33.3)
3 (42.9)
4 (44.4)
7 (15.6)
1 (4.3)
22 (26.5)
8 (19.5)
Missing
7 (22.6)
2 (22.2)
2 (28.6)
3 (33.3)
16 (35.6)
7 (30.4)
25 (30.1)
12 (29.3)

58
18

31

25

711

20

Deceased
n

35

Alive
n

97.1 (95.4-98.2)

44.3 (31.0-56.8)

62.3 (47.5-74.1)

Estimate
(95% CI)

564

35

48

Alive
n

30

23

21

Deceased
n

94.9 (92.9-96.4)

60.3 (46.6-71.6)

68.9 (56.6-78.6)

K-M Estimate
(95% CI)

0.0116 †

0.1019

0.4499

P value †

*

†

Adjusted for maternal age, maternal education, birth weight/gestational age, infant sex, number of birth defects.

Statistically Significant at P<0.05

Study period 1996 to 2008; Kaplan-Meier estimate of study endpoint (December 31, 2008) survival probability.
CI - Confidence Interval
KM - Kaplan-Meier
HR - Hazard Ratio

Pulmonary Valve
Atresia w/
Hypoplastic Right
Ventricle
Pulmonary Valve
Atresia w/o
Hypoplastic Right
Ventricle
Pulmonary Valve
Stenosis

Defect

1.74 (0.94-3.21)

0.77 (0.41-1.46)

1.19 (0.59-2.40)

Adjusted HR (95% CI) *

0.0768

0.4267

0.6333

P value †

Table 9. Kaplan-Meier (KM) survival estimates with 95% confidence intervals (CIs) and Cox proportional hazards ratios (HRs) for children with
congenital pulmonary valve defects using infant sex as a risk factor, Texas Birth Defects Registry data for children born 1996 to 2007
Female (Reference Group)
Male

59

3
6
15
9
6

13
18
26
9
17
493
298
208

Pulmonary Valve Stenosis
Female
Male

97.8 (96.1-98.8)
98.2 (95.8-99.3)
97.2 (93.9-98.7)

49.4 (25.2-69.7)
73.9 (50.9-87.3)

62.4 (45.4-75.4)

81.3 (52.5-93.5)
75.0 (52.6-87.9)

77.5 (61.2-87.6)

154
93
66

4
2

6

3
4

7

10
5
5

4
5

9

4
5

9

94.1 (89.3-96.8)
94.9 (88.2-97.8)
93.0 (83.9-97.0)

50.0 (15.2-77.5)
28.6 (4.1-61.2)

40.0 (16.5-62.8)

42.9 (9.8-73.4)
44.4 (13.6-71.9)

43.8 (19.8-65.6)

591
320
290

12
16

28

19
26

45

†

Statistically Significant at P<0.05

Study period 1996 to 2008; Kaplan-Meier estimate of the study endpoint (December 31, 2008) survival probability.
CI - Confidence Interval
KM - Kaplan-Meier

11
5
6

9

31

Pulmonary Valve Atresia w/
Hypoplastic Right Ventricle
Female
Male
Pulmonary Valve Atresia w/o
Hypoplastic Right Ventricle
Female
Male

27
8
19

18
12

30

13
10

23

95.3 (93.1-96.8)
96.7 (93.2-98.4)
93.9 (90.5-96.0)

40.0 (22.8-56.7)
57.1 (37.1-72.9)

48.3 (35.0-60.3)

57.3 (37.3-73.0)
70.6 (51.8-83.2)

64.2 (50.7-74.9)

0.1357
0.1661

0.0340 a

0.5851
0.1052

0.1767

0.2547
0.2019

0.1081

Table 10. Kaplan-Meier (KM) estimates with log-rank test and 95% confidence intervals (CIs) for survival in children with congenital pulmonary
valve defects using maternal race/ethnicity stratified by infant sex as risk factors, Texas Birth Defects Registry data for children born 1996 to 2007
Non-Hispanic White
Non-Hispanic Black
Hispanic
Survival
Survival
Survival
Defect
P value †
Alive Deceased
Alive Deceased
Alive Deceased
Estimate
Estimate
Estimate
n
n
n
n
n
n
(95% CI)
(95% CI)
(95% CI)

60

15
8 (53.3)
7 (46.7)

41
18 (43.9)
23 (56.1)
169
98 (58.0)
71 (42.0)

7 (43.8)
9 (56.3)

16 (40.0)
24 (60.0)

517
303 (58.6)
214 (41.4)

16

40

1.90 (0.78-4.62) *
2.34 (0.61-8.91)
1.71 (0.50-5.90)

0.1565
0.2138
0.3962

0.4393
0.0570

0.0729

2.32 (0.93-5.83) *
1.75 (0.42-7.27)
3.87 (0.96-15.57)

0.6794
0.0349 †

0.0329 †

1.42 (0.27-7.57)
4.63 (1.12-19.18)

2.93 (1.09-7.85) *

1.45 (0.57-3.68)
2.68 (0.72-10.01)

1.66 (0.80-3.45) *

0.88 (0.21-3.76)
1.17 (0.36-3.83)

1.04 (0.44-2.44) *

0.89 (0.40-1.99) *
637
328 (51.5) 0.66 (0.18-2.46)
309 (48.5) 1.19 (0.43-3.32)

30 (51.7)
28 (48.3)

58

32 (47.1)
36 (52.9)

68

Study period 1996 to 2008
HR - Hazard Ratio
CI - Confidence Interval
a
Due to rounding effect, percentages may not total 100.0%.
†
Statistically Significant at P<0.05
*
Adjusted for maternal age, maternal education, birth weight/gestational age, infant sex, number of birth defects.
**
Adjusted for maternal age, maternal education, birth weight/gestational age, number of birth defects; stratified by sex.

Pulmonary Valve Stenosis
Female
Male

Pulmonary Valve Atresia w/
Hypoplastic Right Ventricle
Female
Male
Pulmonary Valve Atresia w/o
Hypoplastic Right Ventricle
Female
Male

0.7806
0.5330
0.7424

0.4385
0.1416

0.1781

0.8600
0.7974

0.9258

Table 11. Cox-proportional hazards regression model data for risk of mortality in children with congenital pulmonary valve defects using
maternal race/ethnicity by infant sex as a risk factor, Texas Birth Defects Registry data for children born 1996 to 2007
Non-Hispanic White
(Reference Group)
Non-Hispanic Black
Hispanic
Defect
Adjusted HR
Adjusted HR
P value †
P value †
n (%) a
n (%) a
n (%) a
**
(95% CI)
(95% CI) **

61

a

Due to rounding effect, percentages may not total 100.0%.

Table 12. Descriptive statistics for characteristics of infants with pulmonary valve atresia without hypoplastic right ventricle and their birth
mothers, Texas Birth Defects Registry data for children born 1996 to 2007
Non-Hispanic White
Non-Hispanic Black
Hispanic
Total
(n=41)
(n=15)
(n=58)
(n=114)
Characteristic
Deceased
Deceased
Deceased
Deceased
Alive
Alive
Alive
Alive
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
Infants
26
15
6
9
28
30
60
54
Sex
Male
17 (65.4)
6 (40.0)
2 (33.3)
5 (55.5)
16 (57.1)
12 (40.0)
35 (58.3)
23 (42.6)
Female
9 (34.6)
9 (60.0)
4 (66.7)
4 (44.4)
12 (42.9)
18 (60.0)
25 (41.7)
31 (57.4)
Birth weight/gestational age
< 37 wk < 1500 grams
1 (3.8)
1 (6.7)
0 (0.0)
0 (0.0)
1 (3.6)
1 (3.3)
2 (3.3)
2 (3.7)
< 37 wk 1500-2499 grams
2 (7.7)
2 (13.3)
0 (0.0)
2 (22.2)
2 (7.1)
5 (16.7)
4 (6.7)
9 (16.7)
< 37 wk ≥ 2500 grams
3 (11.5)
0 (0.0)
0 (0.0)
0 (0.0)
3 (10.7)
3 (10.0)
6 (10.0)
3 (5.6)
≥ 37 wk < 1500 grams
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
≥ 37 wk 1500-2499 grams
1 (3.8)
2 (13.3)
1 (16.7)
1 (11.1)
1 (3.6)
3 (10.0)
3 (5.0)
6 (11.1)
≥ 37 wk ≥ 2500 grams
19 (73.1)
10 (66.7)
5 (83.3)
6 (66.7)
21 (75.0)
18 (60.0)
45 (75.0)
34 (63.0)
Number of Defects - Males
Isolated
0
0
0
0
0
0
0
0
≤5
8 (47.1)
1 (16.7)
1 (50.0)
2 (40.0)
3 (18.8)
1 (8.3)
12 (48.0)
4 (17.4)
>5
9 (52.9)
5 (83.3)
1 (50.0)
3 (60.0)
13 (81.3)
11 (91.7)
23 (52.0)
19 (82.6)
Number of Defects - Females
Isolated
1
0
0
0
1
0
2
0
≤5
3 (33.3)
2 (22.2)
3 (75.0)
0 (0.0)
4 (33.3)
6 (33.3)
10 (40.0)
8 (25.8)
>5
6 (66.7)
7 (77.8)
1 (25.0)
4 (100.0)
8 (66.7)
12 (66.7)
15 (60.0)
23 (74.2)
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a

Due to rounding effect, percentages may not total 100.0%.

Table 12. Descriptive statistics for characteristics of infants with pulmonary valve atresia without hypoplastic right ventricle and their birth
mothers, Texas Birth Defects Registry data for children born 1996 to 2007
Non-Hispanic White
Non-Hispanic Black
Hispanic
Total
(n=41)
(n=15)
(n=58)
(n=114)
Characteristic
Deceased
Deceased
Deceased
Deceased
Alive
Alive
Alive
Alive
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
Mothers
Maternal Age (years)
< 20
2 (7.7)
2 (13.3)
1 (16.7)
1 (11.1)
5 (17.9)
4 (13.3)
8 (13.3)
7 (13.0)
20-29
13 (50.0)
7 (46.7)
5 (83.3)
5 (55.5)
14 (50.0)
11 (36.7)
32 (53.3)
23 (42.6)
30-39
10 (38.5)
6 (40.0)
0 (0.0)
3 (33.3)
7 (25.0)
15 (50.0)
17 (28.3)
24 (44.4)
> 40
1 (3.8)
0 (0.0)
0 (0.0)
0 (0.0)
2 (7.1)
0 (0.0)
3 (5.0)
0 (0.0)
Maternal Education
< High School
1 (3.8)
1 (6.7)
1 (16.7)
2 (22.2)
10 (35.7)
9 (30.0)
12 (20.0)
12 (22.2)
High School
5 (19.2)
6 (40.0)
2 (33.3)
0 (0.0)
5 (17.9)
5 (16.7)
12 (20.0)
11 (20.3)
> High School
13 (50.0)
5 (33.3)
2 (33.3)
4 (44.4)
3 (10.7)
7 (23.3)
18 (30.0)
16 (29.6)
Missing
7 (26.9)
3 (20.0)
1 (16.7)
3 (33.3)
10 (35.7)
9 (30.0)
18 (30.0)
15 (27.8)
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a

Due to rounding effect, percentages may not total 100.0%.

Table 13. Descriptive statistics for characteristics of infants with pulmonary valve stenosis and their birth mothers, Texas Birth Defects Registry
data for children born 1996 to 2007
Non-Hispanic White
Non-Hispanic Black
Hispanic
Total
(n=517)
(n=169)
(n=637)
(n=1323)
Characteristic
Deceased
Deceased
Deceased
Deceased
Alive
Alive
Alive
Alive
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
Infants
506
11
159
10
610
27
1275
48
Sex
Male
208 (41.1)
6 (54.5)
66 (41.5)
5 (50.0)
290 (47.5)
19 (70.4)
564 (44.2)
30 (62.5)
Female
298 (58.9)
5 (45.4)
93 (58.5)
5 (50.0)
320 (52.5)
8 (29.6)
711 (55.8)
18 (37.5)
Birth weight/gestational age
< 37 wk < 1500 grams
35 (6.9)
2 (18.2)
33 (20.8)
7 (70.0)
62 (10.2)
7 (25.9)
130 (10.2)
16 (33.3)
< 37 wk 1500-2499 grams
41 (8.1)
1 (9.1)
21 (13.2)
3 (30.0)
62 (10.2)
3 (11.1)
124 (9.7)
7 (14.6)
< 37 wk ≥ 2500 grams
33 (6.5)
0 (0.0)
6 (3.8)
0 (0.0)
52 (8.5)
3 (11.1)
91 (7.1)
3 (6.3)
≥ 37 wk < 1500 grams
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
≥ 37 wk 1500-2499 grams
14 (2.8)
0 (0.0)
8 (5.0)
0 (0.0)
16 (2.6)
3 (11.1)
38 (3.0)
3 (6.3)
≥ 37 wk ≥ 2500 grams
383 (75.7)
8 (72.7)
91 (57.2)
0 (0.0)
418 (68.5)
11 (40.7)
892 (70.0)
19 (39.6)
Number of Defects - Males
Isolated
9
0
7
0
28
1
44
1
≤5
132 (7.7)
3 (27.3)
51 (17.6)
2 (20.0)
202 (16.6)
5 (14.8)
385 (13.2)
10 (18.8)
>5
76 (51.4)
3 (54.5)
15 (52.8)
3 (40.0)
88 (54.1)
14 (66.7)
179 (52.9)
20 (58.3)
Number of Defects - Females
Isolated
25
0
10
0
26
1
61
1
≤5
228 (37.9)
1 (18.2)
74 (27.7)
1 (30.0)
227 (26.1)
3 (14.8)
529 (31.0)
5 (18.8)
>5
70 (7.3)
4 (18.2)
19 (8.2)
4 (10.0)
93 (33.1)
5 (33.3)
182 (19.7)
13 (25.0)
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a

Due to rounding effect, percentages may not total 100.0%.

Table 13. Descriptive statistics for characteristics of infants with pulmonary valve stenosis and their birth mothers, Texas Birth Defects Registry
data for children born 1996 to 2007
Non-Hispanic White
Non-Hispanic Black
Hispanic
Total
(n=517)
(n=169)
(n=637)
(n=1323)
Characteristic
Deceased
Deceased
Deceased
Deceased
Alive
Alive
Alive
Alive
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
Mothers
Maternal Age (years)
< 20
39 (7.7)
3 (27.3)
28 (17.6)
2 (20.0)
101 (16.6)
4 (14.8)
168 (13.2)
9 (18.8)
20-29
260 (51.4)
6 (54.5)
84 (52.8)
4 (40.0)
330 (54.1)
18 (66.7)
674 (52.9)
28 (58.3)
30-39
192 (37.9)
2 (18.2)
44 (27.7)
3 (30.0)
159 (26.1)
4 (14.8)
395 (31.0)
9 (18.8)
> 40
15 (3.0)
0 (0.0)
3 (18.9)
1 (10.0)
20 (3.1)
1 (3.7)
38 (3.0)
2 (4.2)
Maternal Education
< High School
37 (7.3)
2 (18.2)
13 (8.2)
1 (10.0)
202 (33.1)
9 (33.3)
252 (19.7)
12 (25.0)
High School
93 (18.4)
3 (27.3)
41 (25.8)
4 (40.0)
96 (15.7)
4 (14.8)
230 (18.0)
11 (22.9)
> High School
191 (37.7)
4 (36.4)
35 (22.0)
2 (20.0)
62 (10.2)
0 (0.0)
288 (22.6)
6 (12.5)
Missing
185 (36.6)
2 (18.2)
70 (44.0)
3 (30.0)
250 (41.0)
14 (51.9)
505 (39.6)
19 (39.6)

CHAPTER 4:
DISPARITIES IN SURVIVAL AND MORTALITY AMONG INFANTS WITH
CONGENITAL TRICUSPID VALVE DEFECTS BY MATERNAL
RACE/ETHNICITY AND INFANT SEX

ABSTRACT
Background: Tricuspid valve atresia is a serious congenital heart defect with poor
survival outcomes for some infants with this defect. Risk factors that contribute to poor
survival outcomes in children with tricuspid valve atresia are not well understood. The
contribution of infant sex and maternal race/ethnicity as risk factors for poor survival has
not been studied for this defect.
Methods: Using data collected by the Texas Birth Defects Registry, we conducted a
retrospective cohort study of 149 singleton infants born to Hispanic, Non-Hispanic (NH)
white, and NH black women in Texas between January 1, 1996 and December 31, 2007
with congenital tricuspid valve atresia. We used Kaplan-Meier survival estimates and
Cox proportional hazards regression ratios (HR) and 95% confidence intervals (CI) to
determine, after adjusting for confounders, whether infant sex or maternal race/ethnicity
affects early childhood survival or risk of mortality for these children.
Results: We found that early childhood survival was considerably lower for NH black
male children (35.7%) and Hispanic males (64.0%) than NH white males (81.0%) with
tricuspid valve atresia (P=0.0269). After adjusting for covariates, we found that NH black
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children with tricuspid valve atresia have 239% increased risk of early childhood
mortality than NH white children (P=0.0062) and the difference in risk was because NH
black males with tricuspid valve atresia have 423% increased risk of early childhood
mortality than NH white males (CI 1.33-20.58; P=0.0179).
Conclusion: The results of our study demonstrate that male sex and NH black maternal
race/ethnicity are risk factors for early childhood mortality in children born with tricuspid
valve atresia. Tricuspid valve atresia is a serious congenital heart defect with poor
survival outcomes for some children with this defect. Further investigation of the role of
infant sex and race/ethnicity in prevention and treatment protocols is warranted to better
understand why this disparity exists and what can be done to improve the outcome for
NH black male children with this defect.
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INTRODUCTION
Birth defects are a primary cause of infant mortality and contribute more than half
of the reported hospitalization costs associated with birth defects in the United States
(Russo 2007). In order to improve the health and survival of infants and children, public
health researchers need to better understand risk factors associated with congenital heart
defects so that effective prevention and treatment programs can be developed and
implemented (Botto, Correa et al. 2001; Nembhard, Waller et al. 2001; Cleves, Ghaffar et
al. 2003; Nembhard, Salemi et al. 2007; Nembhard, Pathak et al. 2008; Nembhard,
Salemi et al. 2009; Fixler, Nembhard et al. 2010; Nembhard, Salemi et al. 2010). We
present our investigation of infant sex and maternal race/ethnicity risk factors
contributing to early childhood survival and risk of mortality for infants born with
tricuspid valve atresia, in an effort to contribute to the effort to better understand outcome
disparities.
Tricuspid Valve Stenosis
Tricuspid valve stenosis is a narrowing of the valve between the right atrium and
right ventricle, restricting normal blood circulation. Tricuspid valve stenosis is
uncommon and little data are available for isolated cases of this defect since tricuspid
valve stenosis is usually associated with other anomalies, especially right ventricular
outflow tract obstruction or atresia with secondary hypoplasia of the right ventricle. Also,
tricuspid valve stenosis is often associated with Ebstein’s anomaly. Since tricuspid valve
stenosis is rare, our study did not evaluate stenosis of the tricuspid valve. We screened
TBDR cases identified with BPA Code 746.100, anomalies of the tricuspid valve, as
tricuspid valve atresia cases for inclusion in our study.
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Tricuspid Valve Atresia
Tricuspid valve atresia is the absence of a valve between the right atrium and
ventricle. Oxygen-depleted blood enters the right atrium but cannot flow to the right
ventricle where blood would normally be pumped to the lungs. In order for blood to get
to the lungs, at least one other heart defect must be present (i.e., patent ductus arteriosus;
atrial septal defect, or ventricular septal defect). Tricuspid valve atresia commonly occurs
in conjunction with the underdevelopment of the right ventricle, a heart defect referred to
as hypoplasia of the right ventricle. Tricuspid valve atresia is a serious congenital heart
defect that can be diagnosed in utero; pregnancy termination may be selected because of
this diagnosis. Tricuspid valve atresia is also associated with Ebstein’s anomaly.
Table 14 provides a summary of study findings for tricuspid valve defects. As
shown in the table, some studies did not differentiate tricuspid valve atresia from
tricuspid valve stenosis. The prevalence of tricuspid valve atresia per 10,000 live births
ranges from 0.49 (95% CI 0.35-0.64) to 3.6 (Ferencz, Rubin et al. 1985; Pradat,
Francannet et al. 2003). Tricuspid valve atresia has been found higher in boys than girls
with a boy to girl ratio=1.45:1 (Samanek 1994). Racial/ethnic disparity has not been
reported specifically for the prevalence of tricuspid valve atresia.
Survival of infants born with tricuspid valve atresia is low. As shown in Table 14,
the 1-year survival for tricuspid valve atresia has been reported as 46 and 57 percent
(Samanek 1992; Samanek and Voriskova 1999). There are no reported data for survival
that differentiate by sex or race/ethnicity. In addition, there are no reported data on the
risk of mortality for congenital tricuspid valve atresia.
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METHODS
Study Design and Data Source
We conducted a retrospective cohort study of 149 infants with congenital
tricuspid valve atresia born in Texas between January 1, 1996 and December 31, 2008.
Data was obtained from the Texas Birth Defects Registry (TBDR), which is maintained
by the Birth Defects Epidemiology and Surveillance Branch of the Texas Department of
State Health Services. In the TBDR population-based active surveillance system TBDR
personnel review medical records to identify infants diagnosed within the first year after
birth with structural and chromosomal birth defects. The TBDR surveillance began in
1995, and since 1999 data have been collected for all births in the state of Texas. TBDR
data are death-to-birth matched by the Texas Vital Statistics Unit using decedent name,
date of death and date of birth, mother’s first and maiden and/or current last names.
The TBDR utilizes six-digit birth defect coding that has evolved through British
Pediatric Association (BPA) extension of the International Classification of Disease,
ninth revision clinical modification diagnostic codes (ICD-9 codes).
Study Population
The study population included all live-born singleton infants with tricuspid valve
anomalies (BPA Code 746.100) born in Texas between January 1, 1996 and December
31, 2008 to NH white, NH black, or Hispanic women of any age. As previously stated,
since tricuspid valve stenosis is rare, our study did not evaluate stenosis of the tricuspid
valve. We screened TBDR cases identified with BPA Code 746.100, anomalies of the
tricuspid valve, as tricuspid valve atresia cases for inclusion in our study. Tricuspid valve
atresia cases with co-occurring heart defects (BPA Codes 745.000 through 747.490) were
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considered for inclusion in our study (Appendix A). However, cases associated with
complex defects such as trisomies or syndromes were excluded. For example, tricuspid
valve atresia associated with Ebstein’s anomaly was not included in our study. All cases
were reviewed by a pediatric cardiologist (Dr. David E. Fixler, M.D.), and tricuspid valve
atresia cases were included in our study only if hypoplastic right ventricle (HRV) (BPA
Code 746.882) was a co-occurring defect.
Covariates
We used infant and maternal covariate information obtained by the TBDR from
birth certificate and medical records. We included infant sex, and maternal race/ethnicity
based on maternal self-report.

Gestational age categorized as term (≥37 completed

weeks) or pre-term (<37 weeks) was included; gestational age was based on last
menstrual period or clinical estimate of gestation from medical records was substituted
when last menstrual period data were missing. Consistent with published literature, we
included birth weight categorized as normal (≥2500 grams), low (1500-2499 grams), or
very low (<1500 grams), as recorded on birth certificates (CDC 1990; Alexander, Kogan
et al. 2003; Nembhard 2011). Also consistent with literature, gestational age and birth
weight were included as a combination variable with six categories: <37 weeks and
<1500 grams; <37 weeks and 1500-2499 grams; <37 weeks and ≥2500 grams; ≥37 weeks
and <1500 grams; ≥37 weeks and 1500-2499 grams; and ≥37 weeks and ≥2500 grams
(Bol, Collins et al. 2006; Nembhard 2011). Maternal age categorized as <20 years, 20-29
years, 30-39 years, and 40+ years and maternal education categorized as high school (12
years), <high school, or >high school were also included. Our analysis also considered
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number of recorded birth defects as reported in medical records as an additional
covariate.
Data Analysis
Descriptive statistics were calculated for main study variables and covariates. We
calculated survival time using date of birth and date of death for deceased infants. When
TBDR data did not have a date of death recorded, infants were censored at the end of the
study period, December 31, 2008.
Early childhood survival was estimated for children with each defect using the
Kaplan-Meier method. Kaplan-Meier survival curves were computed to compare survival
estimates by infant sex and maternal race/ethnicity, and tested the difference between the
curves using the log-rank test.
Unadjusted and adjusted hazard ratios were calculated for mortality using Cox
proportional hazard regression models. The adjusted hazard ratios were computed using a
final regression model developed by backward selection method, removing variables with
less than 10% effect on the hazard ratio. The created models for infant sex and maternal
race/ethnicity stratified by sex used females and NH whites as the reference groups. The
proportional hazards assumption was tested to ensure the assumption was met; we
inspected the proportionality by including time-dependent covariates in the model and
testing for their significance. Variables included in the final model were: maternal age,
maternal education, birth weight/gestational age, and number of defects. Although not all
variables had a major effect on the adjusted hazard ratios (i.e., changing the hazard ratio
by 10% or more), all of the variables included in the final model are biologically
important based on published literature. Results were considered statistically significant
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if the 95% confidence interval excluded 1 or P<0.05. Calculations were performed using
SAS 9.2 for Kaplan-Meier survival estimates and Cox proportional hazards regression
models, and Stata Release 12 for Kaplan-Meier survival plots.
Protection of Human Subjects
The study was conducted with the approval of the University of South Florida
Social and Behavioral Institutional Review Board (IRB) and the Texas Department of
State Health Services.
Power and Sample Size
The formula used to estimate power for this study is an extension of Schoenfeld’s
sample-size formula for the proportional-hazards regression model, solved for power (1β) (Hipwell, Strachan et al. 2000; Shechter, Sharir et al. 2000):

(z1-α/2 + z1-β)2
N = _____________________
P (1-R2) σ2 B2

Where N is the sample size; z1-α/2 and z1-β are standard normal deviates at a twosided significance level α and power (1-β); P is the overall event rate or proportion of
non-censored participants; R2 is the effect size of covariates on the variable of interest; σ
is the standard deviation of the variable of interest; and B is the effect size (log of the
hazard ratio).
We calculated the power to detect hazard ratios of 1.5 and 3.0; the significance
level, alpha, for our study was 0.05. Since our associations indicate risk or protective
exposures, two sided hypotheses were tested. Standard deviation values of 0.5 and 0.7
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were used to show a range of possibilities; the influence of covariates on the outcome, R2
was estimated at 0.15. Based on the study data, estimates of study power were calculated
based on three potential scenarios: 1) an event (death) rate of 5%, 2) an event rate of
10%, and 3) an event rate of 40%.
The results of these calculations are presented in Appendix B. Since our study
size was fairly small for some of our stratified groups, our ability to observe statistically
significant results may be limited.
RESULTS
Tricuspid Valve Atresia
Descriptive statistics for infants born with tricuspid valve atresia are provided in
Table 15. The total number of cases in our study was 149 and included 45 (30.2%) NH
white, 28 (18.8%) NH black, and 76 (51%) Hispanic children. Of these, 96 (64.4%)
children were alive at the end of our study and 53 (35.6%) were deceased. Approximately
79.2% of surviving children and 52.8% of deceased children were born full term (≥37
weeks) and at normal birth weight (≥2500 grams); however, of the approximately 28.3%
of deceased children born pre-term (<37 weeks) and at low (1500-2499) or very low
(<1500 grams) birth weight, most of these children were Hispanic (66.7%). There were
approximately as many males (49.7%) as females (50.3%) that had tricuspid valve
atresia.
Survival and Risk of Childhood Mortality by Infant Sex
Kaplan-Meier estimates, hazard ratios and 95% CI are presented in Table 16.
Early childhood survival for males (63.5%) and females (63.1%) were not different
(P=0.9023). Also, the risk of early childhood mortality was not different for males than
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females with tricuspid valve atresia (HR 1.15; 95% CI 0.64-2.04; P=0.6449) after
adjusting for covariates.
Survival by Maternal Race/Ethnicity and Infant Sex
Kaplan-Meier estimates for children with tricuspid valve atresia are presented in
Table 17, and survival curves are presented in Figure 7. The estimated survival for NH
black (50.0%) and Hispanic (60.5%) children was not statistically different than NH
white children (76.9%), (P=0.0615), or for NH black females (64.3%), Hispanic females
(56.5%), and NH white females (72.6%, P=0.454). However, survival was statistically
different for NH black males (35.70%) and Hispanic males (64.0%) compared to NH
white males (81.0%) with tricuspid valve atresia (P=0.0269).
Risk of Childhood Mortality by Maternal Race/Ethnicity and Infant Sex
Hazard ratios and CI for early childhood mortality in children with tricuspid valve
atresia are presented in Table 18. As shown in the table, NH black children with tricuspid
valve atresia have 239% increased risk of early childhood mortality than NH white
children (HR 3.39; CI 1.41-8.13; P=0.0062), and this difference was because NH black
males with tricuspid valve atresia have 423% increased risk of early childhood mortality
than NH white males (HR 5.23; CI 1.33-20.58; P=0.0179).
Hispanic children born with pulmonary valve stenosis did not have significantly
different risk of early childhood mortality than NH white children (HR 1.43; CI 0.663.10; P=0.3689) collectively, or when stratified by sex: Hispanic males (HR 1.33; CI
0.40-4.41; P=0.6412), Hispanic females (HR 0.67; CI 0.22-2.02; P=0.4753).
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DISCUSSION
We investigated 149 cases of tricuspid valve atresia using the Kaplan-Meier
method with log-rank tests to estimate survival and found that NH black males and
Hispanic males have significantly lower estimates of study endpoint (December 31,
2008) survival probability than NH white males with this defect. After adjusting for
maternal age, maternal education, birth weight/gestational age combinations, and number
of co-occurring defects covariates in the Cox proportional hazards regression model, we
observed statistically significant increased risk of early childhood mortality for NH black
children compared to NH white children, and this was because NH black males have
423% increased risk of early childhood mortality compared to NH white males. As
shown on Figure 7, the majority of deaths occur within the first year after birth.
Literature findings of 1-year survival for cases of tricuspid valve atresia (Table
14) have been reported at 57% (Samanek 1992) and 46% (Samanek and Voriskova
1999). Our Kaplan-Meier survival estimates for tricuspid valve atresia demonstrate
varied survival probabilities: as low as 35.7% (CI 13.0-59.4) in NH black males to 81.0%
(CI 56.9-92.4) in NH white males.
We found infant sex and maternal race/ethnicity differences in early childhood
mortality for children with tricuspid valve atresia, but no significant differences in pattern
of survival. The variables with most influence on the final regression models for were
birth weight/gestational age and number of co-occurring defects.
Tricuspid valve atresia inclusion criteria for our study considered the rare cases of
tricuspid valve stenosis and were included only if HRV was co-occurring. As such, we
did not investigate tricuspid valve atresia as an isolated defect since clinically this defect

75

does not occur unless it is part of another malformation of the heart. For this reason, our
results for tricuspid valve atresia may not be directly comparable to findings of previous
studies.
As discussed previously, tricuspid valve atresia is a serious heart defect that can
be diagnosed in utero and pregnancy termination may be selected because of this
diagnosis. However, prenatal diagnoses of birth defects have been found to be lower
among Hispanic and black women (Waller, Pujazon et al. 2000). Our results may be
biased away from the null as a result of this effect. Our study did not evaluate severity of
defects, paternal race/ethnicity, maternal or paternal environmental factors, family history
of congenital heart valve defects, or severity of defects. The possibility exists that there
are unidentified factors that explain the disparity in early childhood survival for NH black
males.
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Figure 7. Early childhood Kaplan-Meier survival curves for infants with tricuspid valve atresia
by infant sex and maternal race/ethnicity, Texas Birth Defects Registry, 1996-2008
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Study Population
Observation
Estimate (95% CI)
Prevalence Per 10,000 Births
Nembhard et al.
Texas Birth Defects Registry data for 48,391 singleton infants born
TVA/S in Hispanics
1.10 (0.80-1.63)
2010
between January 1 and December 31, 1996 and diagnosed with major
TVA/S in Non-Hispanic Blacks
1.74 (1.31-2.35)
birth defects.
TVA/S in Non-Hispanic Whites
1.11 (0.91-1.46)
Ferencz et al.
Baltimore-Washington Infant Study of 664 infants born in the study
TVA
3.6 (not reported)
1985
area between 1981 and 1982 and diagnosed with congenital heart
disease.
Pradat et al.
California, Sweden and France birth defect registry data for 12,932
TVA in Asians
0.78 (0.43-1.31)
2003
infants born between 1981 and 1992 with congenital heart defects.
TVA in Blacks
0.91 (0.51-1.50)
TVA in Hispanics
0.49 (0.35-0.64)
TVA in Whites
0.70 (0.53-0.86)
Prevalence Comparisons for Race/Ethnicity
Carmichael et al. California Birth Defects Monitoring Program surveillance data for
Lower risk of TVA/S/insufficiency
ARR=0.7 (0.6-0.8)
2004
2,234,846 infants and fetuses born between 1989 and 1997 with
in foreign-born Hispanics than UScongenital malformations.
born Hispanics, African-Americans
or Whites
Prevalence by Sex
Lary and
Metropolitan Atlanta Congenital Defects Program data for 28,965
Higher risk of TVA/S in males
RR=1.16 (1.01-1.35)
Paulozzi 2001
infants born between 1968 and 1995 with at least one major birth
defect.
Samanek 1994
4,409 children born in Bohemia between 1977 and 1984 with
Higher ratio of TVA in boys
Boy to Girl Ratio=1.45:1
congenital heart malformations.
Survival Percent
Samanek 1992
946 Bohemian children with congenital heart disease who died
TVA 1-year survival rate
57% (28-71)
before they were 15 years of age; data were collected between 1952
and 1979.
Samanek and
5,030 children born in Bohemia between 1980 and 1990 with
TVA 1-year survival rate
46% (30-62)
Voriskova 1999
congenital heart disease. Children were followed until age 15, or until
their death before reaching age 15.
ARR – Adjusted Relative Risk
RR – Relative Risk
TVA – Tricuspid Valve Atresia
PR – Prevalence Rate
TVA/S – Tricuspid Valve Atresia/Stenosis

Author

Table 14. Descriptive epidemiology of tricuspid valve defects from published studies, 1985-2010
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a

Due to rounding effect, percentages may not total 100.0%.

Table 15. Descriptive statistics for characteristics of infants with congenital tricuspid valve atresia and their birth mothers, Texas Birth Defects
Registry data for children born 1996 to 2007
Non-Hispanic White
Non-Hispanic Black
Hispanic
Total
(n=45)
(n=28)
(n=76)
(n=149)
Characteristic
Deceased
Deceased
Deceased
Deceased
Alive
Alive
Alive
Alive
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
Infants
35
10
14
14
47
29
96
53
Sex
Male
17 (48.6)
4 (40.0)
5 (35.7)
9 (64.3)
25 (53.2)
14 (48.3)
47 (49.0)
27 (50.9)
Female
18 (51.4)
6 (60.0)
9 (64.3)
5 (35.7)
22 (46.8)
15 (51.7)
49 (51.0)
26 (49.1)
Birth weight/gestational age
< 37 wk < 1500 grams
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
5 (17.2)
0 (0.0)
5 (9.4)
< 37 wk 1500-2499 grams
4 (11.4)
2 (20.0)
0 (0.0)
3 (21.4)
3 (6.4)
5 (17.2)
7 (7.3)
10 (18.9)
< 37 wk ≥ 2500 grams
3 (8.6)
1 (10.0)
0 (0.0)
1 (7.1)
2 (4.3)
3 (10.3)
5 (5.2)
5 (9.4)
≥ 37 wk < 1500 grams
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
≥ 37 wk 1500-2499 grams
1 (2.9)
0 (0.0)
2 (14.3)
2 (14.3)
5 (10.6)
3 (10.3)
8 (8.3)
5 (9.4)
≥ 37 wk ≥ 2500 grams
27 (77.1)
7 (70.0)
12 (85.7)
8 (57.1)
37 (78.7)
13 (44.8)
76 (79.2)
28 (52.8)
Number of Defects - Males
Isolated
0
0
0
0
0
0
0
0
≤5
2 (11.8)
1 (25.0)
0 (0.0)
2 (22.2)
3 (12.0)
1 (7.1)
5 (10.6)
4 (14.8)
>5
15 (88.2)
3 (75.0)
5 (100.0)
7 (77.8)
22 (88.0)
13 (92.9)
42 (89.4)
23 (85.2)
Number of Defects - Females
Isolated
0
0
0
0
0
0
0
0
≤5
2 (11.1)
0 (0.0)
4 (44.4)
2 (40.0)
1 (4.5)
1 (6.7)
7 (14.3)
3 (11.5)
>5
16 (88.9)
6 (100.0)
5 (55.6)
3 (60.0)
21 (95.5)
14 (93.3)
42 (85.7)
23 (88.5)
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a

Due to rounding effect, percentages may not total 100.0%.

Table 15. Descriptive statistics for characteristics of infants with congenital tricuspid valve atresia and their birth mothers, Texas Birth Defects
Registry data for children born 1996 to 2007
Non-Hispanic White
Non-Hispanic Black
Hispanic
Total
(n=45)
(n=28)
(n=76)
(n=149)
Characteristic
Deceased
Deceased
Deceased
Deceased
Alive
Alive
Alive
Alive
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
n (%) a
Mothers
Maternal Age (years)
< 20
5 (14.3)
3 (30.0)
4 (28.6)
1 (7.1)
6 (12.8)
6 (20.7)
15 (15.6)
10 (18.9)
20-29
16 (45.7)
3 (30.0)
10 (71.4)
10 (71.4)
26 (55.3)
16 (55.2)
52 (54.2)
29 (54.7)
30-39
10 (28.6)
4 (40.0)
0 (0.0)
3 (21.4)
14 (29.8)
7 (24.1)
24 (25.0)
14 (26.4)
> 40
4 (11.4)
0 (0.0)
0 (0.0)
0 (0.0)
1 (21.3)
0 (0.0)
5 (5.2)
0 (0.0)
Maternal Education
< High School
6 (17.1)
2 (20.0)
4 (28.6)
1 (7.1)
10 (21.3)
9 (31.0)
20 (20.8)
12 (22.6)
High School
6 (17.1)
4 (40.0)
2 (14.3)
5 (35.7)
10 (21.3)
9 (31.0)
18 (18.8)
18 (34.0)
> High School
12 (34.3)
3 (30.0)
3 (21.4)
4 (28.6)
7 (14.9)
3 (10.3)
22 (22.9)
10 (18.9)
Missing
11 (31.4)
1 (10.0)
5 (35.7)
4 (28.6)
20 (42.6)
8 (27.6)
36 (37.5)
13 (24.5)
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49

Tricuspid Valve Atresia

26

Deceased
n
63.1 (49.9-73.6)

Estimate
(95% CI)
47

Alive
n
27

Deceased
n
63.5 (51.4-73.3)

K-M Estimate
(95% CI)
0.9023

P value

*

Adjusted for maternal age, maternal education, birth weight/gestational age, infant sex, number of birth defects.

Study period 1996 to 2008; Kaplan-Meier estimate of study endpoint (December 31, 2008) survival probability.
CI - Confidence Interval
KM - Kaplan-Meier
HR - Hazard Ratio

Alive
n

Defect

1.15 (0.64-2.04)

Adjusted HR (95% CI) *

0.6449

P value

Table 16. Kaplan-Meier (KM) survival estimates with 95% confidence intervals (CIs) and Cox proportional hazards ratios (HRs) for children with
congenital tricuspid valve atresia using infant sex as a risk factor, Texas Birth Defects Registry data for children born 1996 to 2007
Female (Reference Group)
Male

82

17

35
18
4

10
6
81.0 (56.9-92.4)

76.9 (61.1-86.9)
72.6 (47.9-87.0)
5

14
9
9

14
5
35.7 (13.0-59.4)

50.0 (30.6-66.6)
64.3 (34.3-83.3)
25

47
22
14

29
15

†

Statistically Significant at P<0.05

Study period 1996 to 2008; Kaplan-Meier estimate of the study endpoint (December 31, 2008) survival probability.
CI - Confidence Interval
KM - Kaplan-Meier

Male

Tricuspid Valve Atresia
Female

64.0 (46.9-76.9)

60.5 (48.1-70.9)
56.5 (37.2-71.9)

0.0615
0.4540
0.0269 †

Table 17. Kaplan-Meier (KM) estimates with log-rank test and 95% confidence intervals (CIs) for survival in children with congenital tricuspid
valve atresia using maternal race/ethnicity stratified by infant sex as risk factors, Texas Birth Defects Registry data for children born 1996 to 2007
Non-Hispanic White
Non-Hispanic Black
Hispanic
Survival
Survival
Survival
Defect
P value †
Alive Deceased
Alive Deceased
Alive Deceased
Estimate
Estimate
Estimate
n
n
n
n
n
n
(95% CI)
(95% CI)
(95% CI)

83

45
24 (53.3)
21 (46.7)

28
14 (50.0)
14 (50.0)

3.39 (1.41-8.13) *
0.86 (0.23-3.24)
5.23 (1.33-20.58)

0.0062 †
0.8187
0.0179 †
76
37 (48.7)
39 (51.3)

1.43 (0.66-3.10) *
0.67 (0.22-2.02)
1.33 (0.40-4.41)

Study period 1996 to 2008
HR - Hazard Ratio
CI - Confidence Interval
a
Due to rounding effect, percentages may not total 100.0%.
†
Statistically Significant at P<0.05
*
Adjusted for maternal age, maternal education, birth weight/gestational age, infant sex, number of birth defects.
**
Adjusted for maternal age, maternal education, birth weight/gestational age, number of birth defects; stratified by sex.

Tricuspid Valve Atresia
Female
Male

0.3689
0.4753
0.6412

Table 18. Cox-proportional hazards regression model data for risk of mortality in children with congenital tricuspid valve defects
using maternal race/ethnicity by infant sex as a risk factor, Texas Birth Defects Registry data for children born 1996 to 2007
Non-Hispanic White
(Reference Group)
Non-Hispanic Black
Hispanic
Defect
Adjusted
HR
Adjusted
HR
P value †
n (%) a
n (%) a
n (%) a
P value †
**
(95% CI)
(95% CI) **

CHAPTER 5:
CONCLUSIONS AND RECOMMENDATIONS

The purpose of this study was to determine if the probability of early childhood
survival or risk of mortality varies by infant sex or maternal race/ethnicity in children
with congenital heart valve defects in order to expand the existing knowledge of the risk
factors for these birth defects, and provide public health and clinical practitioners with
insight for their efforts to implement improvements in the prevention and treatment of
these defects. We were able to meet our study aims; we demonstrated that there were
infant sex and maternal racial/ethnic disparities in early childhood survival and risk of
mortality for children with congenital heart valve defects.
Our study found that early childhood survival was better for males than females
with aortic valve atresia and stenosis. However, after adjusting for confounders, we did
not find statistically significant differences in risk of early childhood mortality for either
of these defects. We also did not find any differences by race/ethnicity.
For pulmonary valve stenosis we found that early childhood survival was poorer
for males than females, and poorer for NH black and Hispanic children than NH white
children.
After adjusting for covariates, we determined that NH black children with
pulmonary valve atresia and HRV have 193% higher risk of early childhood mortality
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than NH white children; this increased risk was because NH black males with this defect
have 363% higher risk of early childhood mortality compared to NH white males.
For tricuspid valve atresia we found poorer survival for NH black males and
Hispanic males than NH white males. NH black children had 239% increased risk of
early childhood mortality than NH white children, and NH black males had 423%
increased risk of early childhood mortality than NH white males with tricuspid valve
atresia.
The study had several strengths: 1) the results of our study are highly
generalizable since the TBDR is a multi-ethnic population-based active surveillance
system for all births in Texas; 2) our study had a large sample size, data for 2070 infants
with congenital heart valve defects, providing us with adequate study size to observe
statistically significant associations by infant sex and maternal race/ethnicity; and 3)
verified defect diagnoses improved accuracy of the data.
Our study also had some potential limitations. The numbers of cases of some
defects (i.e., aortic valve stenosis or pulmonary valve atresia without HRV) may not have
been large enough to observe associations for three racial/ethnic categories after
stratifying by infant sex. Perhaps if the study size was larger for these defects, we would
have observed statistically significant lower risk of mortality in Hispanic females with
aortic valve stenosis compared to NH white females (P=0.0728), or higher risk of
mortality in NH black children (P=0.0729) or NH black males (P=0.0570) with
pulmonary valve atresia and HRV, compared to NH whites. Power and sample size
calculations (Appendix B) indicate power was limited under some conditions.
Nonetheless, we observed statistically significant disparities for several defects.
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Another potential limitation is that the model included co-occurring birth defects
as a continuous variable, but did not differentiate between protective (e.g., patent ductus
arteriosus, atrial septal defect, or ventricular septal defect) and deleterious defects.
Survival for children with some congenital heart valve defects depends on the presence of
another defect to allow blood to flow through the heart. For example: infants with aortic
valve atresia may have better chances of survival if patent ductus arteriosus persists;
pulmonary valve atresia is commonly present in conjunction with ventricular septal
defect; and infants with tricuspid valve atresia may have better chances of survival if
patent ductus arteriosus, atrial septal defect, or ventricular septal defect are present.
Future studies should assess the effects of protective and deleterious co-occurring defects
when adjusting for covariates.
We also did not control for the potential confounding effects of initiation of
prenatal care for mothers. Prenatal detection of congenital heart defects has been found to
be related to elective termination of pregnancy (Stoll 2002) and varies by race/ethnicity;
prenatal diagnoses of birth defects is lower among Hispanic and black women (Waller,
Pujazon et al. 2000). As such, it is possible that more NH white mothers had prenatal
diagnosis of severe congenital heart defects and elected to terminate the pregnancy more
often than NH black or Hispanic mothers. As a result, our results may be biased away
from the null as a result of this effect.
We did not include geographic variables in our study. Nembhard, Salemi et al.
(2011) used a rural urban commuting area (RUCA) variable in their regression model for
determination of hazard ratios. Our data were de-identified, so we did not have access to
information necessary to include this variable in our regression models.

86

We used case inclusion and exclusion criteria that are rather unique to our study.
For example, we investigated pulmonary valve atresia with and without HRV. Although
our criteria allowed us to observe associations for these specific defects, our findings are
not directly comparable with previous investigations. Further, our pediatric-cardiologist
verification of defect diagnosis was based on data collected by TBDR personnel, not on
direct review of clinical records. Our cardiologist review of the data for defect
verification was conducted by an individual expert, not a panel of experts, which may be
considered subjective and lacking confirmatory quality assurance of the expert review.
For the combined birth weight and gestational age covariate in our study, one
category of this variable (birth weight <1500 grams and gestational age ≥37 weeks) had
only one infant meeting these criteria; however, on further evaluation we observed that
the gestational age was reported incorrectly. We calculated gestational age using date of
birth and date of last menstrual period and found that this infant was less than 37 weeks
gestation when born. We corrected the data and as a result there were no children meeting
the criteria of birth weight <1500 grams and gestational age ≥37 weeks in our study.
Another covariate in our study was self-reported maternal education, and a
considerable portion of our study population had missing information on this variable.
We elected to consider “missing” as a variable category in our analysis because there was
a possibility of systematic differences in the reasons why a mother may choose to not
report level of education completed. We observed high proportions of deceased children
for mothers with high school or less than high school education; there was a possibility
that the missing information could have biased our determinations toward the null in our
adjusted hazard model.
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Our study was a population-based retrospective study using TBDR data for all
children born in Texas between 1996 and 2007. Our findings are highly generalizable
since our data were population-based; however the racial/ethnic demographics of Texas
differ from other regions of the United States.
In conclusion, our investigation identified racial/ethnic associations by infant sex
that have yet to be reported, and enhanced the findings of previous investigations to
advance the understanding of the pathogenesis and etiology of congenital heart valve
defects. Our findings provide a foundation for additional research. We recommend a
future investigation that includes RUCA variables and considers categories of cooccurring defects and/or protective vs. deleterious defects. Similar studies using active
surveillance data for other geographic regions would be useful to determine if disparities
are present in other demographic populations.
Disparities in survival probability and risk of mortality indicate genetics may
contribute to the outcome. Our study did not investigate paternal variables; future
investigations of the contribution of paternal race/ethnicity, family history of congenital
heart valve defects, and maternal and paternal environmental exposures may provide
useful information to further the understanding of the etiology of these defects.
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APPENDIX A
TEXAS BIRTH DEFECTS REGISTRY BPA CODES FOR CONGENITAL
HEART DEFECTS
Table A1. Texas Birth Defects Registry BPA Codes for congenital heart defects
745 Bulbus Cordis Anomalies and Anomalies of Cardiac Septal Closure
745.000 Common truncus
Persistent truncus arteriosus
Absent septum between aorta and pulmonary artery
745.010 Aortic septal defect
Includes: Aortopulmonary window
Excludes: Atrial septal defect
745.100 Transposition of great vessels, complete (no VSD)
D-transposition with no VSD
745.110 Transposition of great vessels, incomplete (with VSD)
D-transposition with a VSD
Taussig-Bing syndrome
Transposition with inlet VSD
Transposition with perimembraneous VSD
Excludes: Transposition with muscular VSD
745.120 Corrected transposition of great vessels,
L-transposition, ventri in version
Ventricular inversion
Excludes: Dextrocardia
745.180 Other specified transposition of great vessels
Includes: Double outlet right ventricle
Double outlet left ventricle
745.190 Unspecified transposition of great vessels
745.200 Tetralogy of Fallot
Diagnosis of Tetralogy of Fallot assumes pulmonary valve defects and right
ventricular hypertrophy, these defects are not coded separately
745.300 Single ventricle
745.400 Ventricular septal defect
745.400 Roger's disease
745.410 Eisenmenger's syndrome
745.420 Gerbode defect
745.480 Other specified ventricular septal defect (VSD)
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Table A1. Texas Birth Defects Registry BPA Codes for congenital heart defects
745.490 Ventricular septal defect (VSD)
745.500 Ostium secundum type atrial septal defect
Nonclosure of foramen ovale
Patent foramen ovale (PFO)
745.510 Ostium (septum) secundum defect
Secundum ASD
Fossa ovalis atrial septal defect
Fenestrated ASD
745.520 Lutembacher's syndrome
745.580 Other specified atrial septal defect
745.590 ASD (atrial septal defect)
Auricular septal defect
Partial foramen ovale
PFO vs. ASD
PFO vs secundum ASD
745.600 Endocardial cushion defects
Ostium primum defects
Primum ASD
745.610 Single common atrium, cor triloculare biventriculare
745.630 Common atrioventricular canal 1
Includes: Complete AV canal defect 1
745.680 Other specified cushion defect
745.690 Endocardial cushion defect, NOS
745.700 Cor biloculare
745.800 Other specified defects of septal closure
745.900 Unspecified defect of septal closure
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Table A1. Texas Birth Defects Registry BPA Codes for congenital heart defects
746 Other Congenital Anomalies of Heart
746.000 Anomalies of pulmonary valve
Atresia, hypoplasia of pulmonary valve
Absent pulmonary valve
See 746.995 if valve is not specified (e.g., "pulmonary atresia")
746.010 Stenosis of pulmonary valve
Small pulmonary valve
See 746.995 if valve not specified (e.g., "pulmonary stenosis")
Excludes: Pulmonary infundibular stenosis
746.020 Pulmonary valve insufficiency or regurgitation, congenital
746.080 Other specified anomalies of pulmonary valve
Thickened pulmonary valve
Dysplastic pulmonary valve
Enlarged pulmonary valve
Dilated pulmonary valve
Bicuspid pulmonary valve
Redundant pulmonary valve
Dysmorphic pulmonary valve
Excludes: Pulmonary infundibular
Stenosis (Use 746.830)
746.090 Unspecified anomaly of pulmonary valve
746.100 Anomalies of the tricuspid valve
Tricuspid atresia, stenosis, or hypoplasia
Right atrioventricular (AV) atresia, stenosis, or hypoplasia
Bicuspid right atrioventricular (AV) valve
Bicuspid tricuspid valve
Cleft right atrioventricular (AV) valve
Cleft tricuspid valve
Dysplastic right atrioventricular (AV) valve
Dysplastic tricuspid valve
Small right atrioventricular (AV) valve
Small tricuspid valve
746.105 Tricuspid valve insufficiency or regurgitation, congenital
Right atrioventricular (AV) valve insufficiency or regurgitation, congenital
Tricuspid valve incompetence
Excludes: Ebstein's anomaly
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Table A1. Texas Birth Defects Registry BPA Codes for congenital heart defects
746.180 Other anomalies of the tricuspid valve
Abnormal tricuspid valve
Dilated right atrioventricular (AV) valve
Dilated tricuspid valve
Enlarged right atrioventricular (AV) valve
Enlarged tricuspid valve
Redundant tricuspid valve
Right atrioventricular (AV) valve aneurysm
Thickened right atrioventricular (AV) valve
Thickened tricuspid valve
Tricuspid valve aneurysm
Tricuspid valve prolapse
746.200 Ebstein's anomaly
746.300 Congenital stenosis of aortic valve
Includes: Congenital aortic stenosis
Subvalvular aortic stenosis
Small aortic valve
Excludes: Supravalvular aortic stenosis
746.400 Congenital insufficiency of aortic valve
Aortic valve insufficiency or regurgitation, congenital bicuspid aortic valve
Aortic valve incompetence
746.480 Other specified anomalies of the aortic valves
Includes: Aortic valve atresia
Aortic annulus defects
Hypoplastic aortic valve
Dysplastic aortic valve
Thickened aortic valve
Absent aortic valve
Dysmorphic aortic valve
Quadricuspid aortic valve
Narrow aortic annulus
Excludes: Supravalvular aortic stenosis
746.490 Unspecified anomalies of the aortic valves
Abnormal aortic valve
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746.500 Congenital mitral stenosis
Congenital left atrioventricular (AV) stenosis
Thickened mitral valve
Thickened left atrioventricular (AV) valve
746.505 Absence, atresia, or hypoplasia of mitral valve
Abnormal mitral valve
Absence, atresia, or hypoplasia of left atrioventricular (AV) valve
Cleft left atrioventricular (AV) valve
Cleft mitral valve
Double orifice mitral valve
Dysmorphic mitral valve
Dysplastic left atrioventricular (AV) valve
Dysplastic mitral valve
Left atrioventricular (AV) valve prolapse
Mitral valve anomaly
Mitral valve prolapse
Parachute left atrioventricular (AV) valve
Parachute mitral valve
746.600 Mitral valve insufficiency or regurgitation, congenital
Left atrioventricular (AV) valve insufficiency or regurgitation, congenital
746.700 Hypoplastic left heart syndrome
Diagnosis of hypoplastic left heart syndrome assumes the following
diagnoses:
Hypoplastic left ventricle - 746.881
Mitral valve anomalies - 746.5 and 746.6
Aortic valve anomalies - 746.3 and 746.4
Atresia or hypoplasia of the ascending aorta - 747.210
When mitral valve or aortic valve are absent/atretic, those defects are
diagnosed separately.
Atresia, or marked hypoplasia of the ascending aorta and defective
development of
the left ventricle (with mitral valve involvement)
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746.800 Other specified anomalies of the heart
Dextrocardia without situs inversus (situs solitus)
Dextrocardia with no mention of situs inversus
Excludes: Dextrocardia with situs inversus (Use 759.300)
Dextrocardia with left congenital diaphragmatic hernia
746.820 Cor triatriatum
746.830 Pulmonary infundibular (subvalvular) stenosis
746.840 Trilogy of Fallot
746.850 Anomalies of pericardium
746.860 Anomalies of myocardium
Cardiomegaly, congenital,
Cardiomyopathy, congenital
Cardiomyopathy, hypertrophic
Rhabdomyoma (heart)
Ventricular hypertrophy, bilateral 2
Ventricular septal thickening
Ventricular septal hypertrophy
Excludes: Ventricular hypertrophy, unilateral (Use 746.886)
746.870 Congenital heart block
746.880 Other specified anomalies of heart
Includes: Ectopia (ectopic) cordis (mesocardia), conduction defects,
Shone’s complex
Tumor of the heart
Hypoplastic heart
Long Q-T syndrome
Left ventricular outflow tract obstruction
Right ventricular outflow tract obstruction
746.881 Hypoplastic left ventricle
Excludes: Hypoplastic left heart syndrome
746.882 Hypoplastic right heart (ventricle)
Uhl's disease
746.883 Hypoplastic ventricle
746.885 Anomalies of coronary artery or sinus
Dilated coronary sinus
Excludes: Dilated coronary sinus when there is a left superior vena cava
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746.886 Ventricular hypertrophy, unilateral (right or left)
Excludes: Ventricular hypertrophy, bilateral
746.887 746.887 Other defects of the atria
Hypoplastic atrium
Excludes: Congenital Wolfe-Parkinson-White
Rhythm anomalies
746.900 Unspecified anomalies of heart
Unspecified anomalies of heart valves
Truncal valve
Truncal valve insufficiency and regurgitation
Truncal valve stenosis
Narrow truncal valve
Single atrioventricular valve
Single atrioventricular valve insufficiency and regurgitation
746.910 Anomalous bands of heart
746.920 Acyanotic congenital heart disease, NOS
746.930 Cyanotic congenital heart disease, NOS
Blue baby
746.990 Unspecified anomaly of heart:
Includes: Congenital heart disease (CHD)
746.995 "Pulmonic" or "pulmonary" atresia, stenosis, or hypoplasia, NOS (no
mention of valve or artery)
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747 Other Congenital Anomalies of Circulatory System
747.000 Patent ductus arteriosus
747.100 Coarctation of aorta
Preductal (proximal) coarctation of aorta
747.110 Postductal (distal) coarctation of aorta
747.090 Unspecified coarctation of aorta
Juxtaductal coarctation of aorta
747.200 Other anomalies of aorta
Atresia of aorta
Absence of aorta
Atrophy of aorta
Pseudotruncus arteriosus
Stenosis of aorta
747.210 Hypoplasia of aorta
Tubular hypoplasia of aorta
Small aorta
Narrowing of aorta
Proximal distal transverse arch hypoplasia
Narrow aortic isthmus
Hypoplastic aortic arch
747.215 Interrupted aortic arch
747.220 Supra-aortic stenosis (supravalvular)
Excludes: Aortic valve stenosis, congenital (See 746.300)
747.230 Persistent right aortic arch
747.240 Aneurysm of sinus of Valsalva
747.250 Vascular ring (aorta)
Double aortic arch
Includes: Vascular ring compression of trachea
747.260 Overriding aorta
Dextroposition of aorta
Malaligned aorta
747.270 Congenital aneurysm of aorta
Congenital dilatation of aorta
Enlarged aorta
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747.280

747.290
747.300

747.310
747.320

747.325

747.330

747.340
747.380

747.390
747.400

747.410
747.420
747.430

Other specified anomalies of aorta
Collateral vessel involving aorta 1
Pseudocoarctation of aorta
Elongation of aorta
Unspecified anomalies of aorta
Anomalies of pulmonary artery
Pulmonary artery atresia, absence, or agenesis
Use 746.995 if artery or valve is not specified
Pulmonary artery atresia with septal defect
Pulmonary artery stenosis
Supravalvular pulmonary stenosis
Pulmonary artery narrowing
Use 746.995 if artery or valve is not specified
Peripheral pulmonary artery stenosis
Includes: peripheral pulmonic stenosis (PPS)
pulmonary artery branch stenosis
peripheral pulmonic stenosis (PPS) murmur
Aneurysm of pulmonary artery
Dilatation of pulmonary artery
Enlarged pulmonary artery
Pulmonary arteriovenous malformation or aneurysm
Other specified anomaly of pulmonary artery
Includes: Pulmonary artery hypoplasia
Small pulmonary artery
Overriding pulmonary artery
Collateral vessel involving pulmonary artery (and not aorta) 1
Pulmonary vascular or artery sling
Unspecified anomaly of pulmonary artery
Anomalies of great veins
Stenosis of vena cava (inferior or superior)
Small vena cava (inferior or superior)
Persistent left superior vena cava
Bilateral superior vena cava
(TAPVR) Total anomalous pulmonary venous return
Partial anomalous pulmonary venous return
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747.440 Anomalous portal vein termination
747.450 Portal vein - hepatic artery fistula
747.480 Other specified anomalies of great veins
Enlarged vena cava (inferior or superior)
Pulmonary vein atresia
Pulmonary vein stenosis
Dilated vena cava (inferior or superior)
Absent vena cava (inferior or superior)
Interrupted inferior vena cava
Bilateral inferior vena cava
Anomalous pulmonary venous return – total/partial not specified
Small pulmonary veins
Excludes: Absent left superior vena cava (LSVC) which would be normal
747.490 Unspecified anomalies of great veins
747.500 Absence or hypoplasia of umbilical artery
Single umbilical artery
Two-vessel cord
Umbilical artery hypoplasia
747.600 Other anomalies of peripheral vascular system
Stenosis of renal artery
747.610 Other anomalies of renal artery
Absent renal artery
747.620 Arteriovenous malformation (peripheral)
Excludes: Pulmonary (747.340)
Cerebral (747.800)
Retinal (743.510)
747.630 Congenital phlebectasia
Congenital varix
747.640 Other anomalies of peripheral arteries
Includes: Aberrant subclavian artery
Common brachiocephalic trunk
Aberrant innominate artery
Absent carotid artery
Anomalous carotid artery
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747.650 Other anomalies of peripheral veins
Hemiazygos vein anomalies
Hypoplastic innominate vein
Hypoplastic jugular vein
Hepatic vein stenosis
747.680 Other anomalies of peripheral vascular system
Includes: Four vessel umbilical cord
747.690 Unspecified anomalies of peripheral vascular system
747.800 Other specified anomalies of circulatory system
Arteriovenous (malformation) aneurysm of brain
747.810 Other anomalies of cerebral vessels
Includes: Anomalies of Vein of Galen
747.880 Other specified anomalies of circulatory system
Endothelial vessel
Collateral vessel (not involving aorta or pulmonary artery) 1
Excludes: Congenital aneurysm:
Coronary (746.880)
Peripheral (747.640)
Pulmonary (747.330)
Retinal (743.510)
Ruptured cerebral arteriovenous
Aneurysm
Ruptured cerebral aneurysm
747.900 Unspecified anomalies of circulatory system
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APPENDIX B:
ESTIMATED POWER CALCULATIONS AND ASSUMPTIONS
The formula used to estimate power for this study is an extension of Schoenfeld’s
sample-size formula for the proportional-hazards regression model, solved for power (1β) (Hipwell, Strachan et al. 2000; Shechter, Sharir et al. 2000). We performed power
calculations using Power Analysis and Sample Size (PASS) software by NCSS (Kaushik,
Leon et al. 2000).
(z1-α/2 + z1-β)2
N = _____________________
P (1-R2) σ2 B2
Where N is the sample size; z1-α/2 and z1-β are standard normal deviates at a twosided significance level α and power (1-β); P is the overall event rate or proportion of
non-censored participants; R2.is the effect size of covariates on the variable of interest; σ
is the standard deviation of the variable of interest; and B is the effect size (log of the
hazard ratio).
In order to calculate an estimate of power for this study, several assumptions have
been used to select parameter values for inclusion in the formula. Our study was
conducted using TBDR data for 2070 singleton infants born between January 1, 1996 and
December 31, 2007 with congenital heart valve defects. We found that approximately
48.4% of our cases were Hispanic (1001), 39.8% were non-Hispanic white (824), and
11.8% were non-Hispanic black (245); our study included 219 infants with aortic valve
atresia, 300 with had aortic valve stenosis, 124 with pulmonary valve atresia and HRV,
114 with pulmonary valve atresia without HRV, 1323 with pulmonary valve stenosis, and
149 with tricuspid valve atresia.
We calculated the power to detect hazard ratios of 1.5 and 3.0; the significance
level, alpha, for our study was 0.05. Since our associations indicate risk or protective
exposures, two sided hypotheses were tested.
We calculated power using standard deviation values of 0.5 and 0.7 to show a
range of possibilities, and assumed that the outcome was influenced by covariates such
that the value of R2 was assumed to be 0.15. These values were selected as moderate
points from a range of potential values.
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Based on the study data, estimates of study power were calculated based on three
potential scenarios: 1) an event (death) rate of 5%, 2) an event rate of 10%, and 3) an
event rate of 40%.
The results of these calculations are presented in Table B1. As shown in the table,
estimated study power varies considerably for the various scenarios of our study.
Although our study size was fairly small for some of our stratified groups, we were able
to observe statistically significant results although the power to detect these results may
have been limited.
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Table B1. Estimated power for various sample sizes, standard deviations, and event rates
R-Squared
Sample

Reg.

S.D.

Event

X1 vs

Size

Coef.

of X1

Rate

Other X's

Sided

(N)

(B)

(SD)

(P)

(R2)

Alpha

Beta

0.03811

20

0.4055

0.5

0.05

0.15

0.05

0.96189

0.04802

50

0.4055

0.5

0.05

0.15

0.05

0.95198

0.06154

100

0.4055

0.5

0.05

0.15

0.05

0.93846

0.07304

20

1.0986

0.5

0.05

0.15

0.05

0.92696

0.12318

50

1.0986

0.5

0.05

0.15

0.05

0.87682

0.20396

100

1.0986

0.5

0.05

0.15

0.05

0.79604

0.04498

20

0.4055

0.5

0.1

0.15

0.05

0.95502

0.06154

50

0.4055

0.5

0.1

0.15

0.05

0.93846

0.08552

100

0.4055

0.5

0.1

0.15

0.05

0.91448

0.10679

20

1.0986

0.5

0.1

0.15

0.05

0.89321

0.20396

50

1.0986

0.5

0.1

0.15

0.05

0.79604

0.35999

100

1.0986

0.5

0.1

0.15

0.05

0.64001

0.07618

20

0.4055

0.5

0.4

0.15

0.05

0.92382

0.13051

50

0.4055

0.5

0.4

0.15

0.05

0.86949

0.21836

100

0.4055

0.5

0.4

0.15

0.05

0.78164

0.2989

20

1.0986

0.5

0.4

0.15

0.05

0.7011

0.61976

50

1.0986

0.5

0.4

0.15

0.05

0.38024

0.89306

100

1.0986

0.5

0.4

0.15

0.05

0.10694

0.04473

20

0.4055

0.7

0.05

0.15

0.05

0.95527

0.06103

50

0.4055

0.7

0.05

0.15

0.05

0.93897

0.0846

100

0.4055

0.7

0.05

0.15

0.05

0.9154

0.10547

20

1.0986

0.7

0.05

0.15

0.05

0.89453

0.20075

50

1.0986

0.7

0.05

0.15

0.05

0.79925

0.35398

100

1.0986

0.7

0.05

0.15

0.05

0.64602

0.05593

20

0.4055

0.7

0.1

0.15

0.05

0.94407

0.0846

50

0.4055

0.7

0.1

0.15

0.05

0.9154

0.12873

100

0.4055

0.7

0.1

0.15

0.05

0.87127

0.16921

20

1.0986

0.7

0.1

0.15

0.05

0.83079

0.35398

50

1.0986

0.7

0.1

0.15

0.05

0.64602

0.61106

100

1.0986

0.7

0.1

0.15

0.05

0.38894

0.11128

20

0.4055

0.7

0.4

0.15

0.05

0.88872

0.21487

50

0.4055

0.7

0.4

0.15

0.05

0.78513

0.38024

100

0.4055

0.7

0.4

0.15

0.05

0.61976

0.5181

20

1.0986

0.7

0.4

0.15

0.05

0.4819

0.88701

50

1.0986

0.7

0.4

0.15

0.05

0.11299

0.9942

100

1.0986

0.7

0.4

0.15

0.05

0.0058

Power
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